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ABSTRACT 
HISTONE DEACETYLASE INHIBITION-MEDIATED 
CYTOTOXICITY OF OLiGODENDROCYTES 
T oros A. Dincman 
August 23,2011 
Recent studies indicate post-translational deacetylation by members of the 
superfamily of histone deacetylase complexes (HDACs) is necessary for 
oligodendrocyte precursor cell (OPC) differentiation into mature oligodendrocytes 
(OLs). However, it remains unknown if transient HDAC inhibition may promote 
OPC survival as has been shown in other cell types and neurological disease 
models. Chapter 2 demonstrates the development of a novel primary culture of 
OPCs from mouse pup cortices enriching the 04+ OPC population using 
Magnetic Activated Cell Sorting (MACS) technology. Once plated, OPCs were 
glial fibrillary acidic protein- (GFAP-), A2B5+, NG2+, and 04+. When induced to 
differentiate, mouse OPCs became either more complex 04+ and 01 + 
oligodendrocytes (OLs) or GFAP+ astrocytes. Bi-potentiality is lost in co-culture, 
however, with rat embryonically derived dorsal root ganglia (DRG) as mature 
OLs aligned with DRG neurites. 
In Chapter 3, following OPC treatment with the FDA approved pan-HDAC 
inhibitor suberoylanilide hydroxamic acid (SAHA), approximately 65% reduction 
in cell survival relative to vehicle-treated OPCs was observed. SAHA-mediated 
death of OPCs induces apoptosis partly by caspase activation with improvement 
vii 
of OPC survival when SAHA is accompanied by treatment with the general 
caspase inhibitor q-vd-oph. SAHA treatment of CNP-EGFP transgenic mouse 
pups increased the number of caspase activated apoptotic cortical OPCs 
compared to vehicle treated pups (p < 0.05). 
In Chapter 4, we extended this study to spinal cord-derived rat primary 
OPCs to determine putative mechanism(s). Rat OPCs were similarly susceptible 
to SAHA-mediated HDACi. SAHA treatment of rat OPCs increased 
phosphorylated histone H2A.X+ (yH2AX) indicating the presence of HDACi-
mediated DNA double-strand breaks. SAHA treatment also increased 
phosphorylated p53 and cleaved caspase 3 levels suggesting HDACi P53 
mediated, caspase-dependant rat OPC apoptosis. 
These results provide strong evidence of HDACi-mediated apoptosis of 
normal mouse pup and adult rat OPCs. SAHA is currently involved in more than 
180 clinical trials, some of which include a pediatric patient population, and is in 
consideration for use in the treatment of psychiatric and neurodegenerative 
conditions. These results strongly suggest that such clinical use of SAHA may 
negatively impact OPC survival and potentially be detrimental to the myelinating 
brain and spinal cord. 
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SCI INCIDENCE AND PATHOLOGY 
SCI is the second leading cause of paralysis in the United States with over 
1.2 million people currently suffering from symptomology secondary to long-
standing SCI. SCI occurs most often in males (61 %) with the average age of 
those who reported paralysis secondary to SCI at 48 years old having, on 
average, being 14 years removed from their injury (www.cdrf.org). Estimated 
lifetime costs for a young male with a high cervical SCI are over $3 million with 
over $770,000 in costs during the first year of the injury 
(www.spinalcord.uab.edu). With both a pressing need to improve the quality of 
life for these patients and to help reduce individual and national healthcare costs, 
continued SCI research into new promising therapeutic modalities is absolutely 
necessary. 
Spinal cord contusion results in immediate cell death due to extensive 
hemorrhage and sheer force of the impact causing significant cellular membrane 
disruption. These primary processes result in widespread demyelination, 
oligodendrocyte (OL) and neuronal cell death, microvascular dysfunction, and a 
massive inflammatory response. Secondary processes characterized by 
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continuing oligodendroglial apoptosis and subsequent demyelination, chronic 
presence of activated inflammatory cells, Wallerian degeneration, and ultimately 
the formation of a glial scar surrounding a cyst-like cavitation result in the gradual 
development of the full destructive pathology of the injured spinal cord (Hall and 
Springer, 2004; Totoiu and Keirstead, 2005; Thuret et aI., 2006; Ankeny and 
Popovich, 2009). 
SCI pathological hallmarks also consist of often spared tissue that may 
play an important role in functional recovery. Near the injury epicenter, a rim of 
intact, myelinated axonal tracts is often present (Sahni and Kessler, 2010). 
However, as this is observed in otherwise neurologically complete lesions 
following human SCI, its relevance, particularly in spontaneous recovery 
following SCI, remains unclear. Furthermore, endogenous reparative processes 
are activated immediately following SCI (Thuret et aI., 2006). These largely come 
in two forms to fulfill two different purposes: (1) to limit the extent of tissue 
damage and isolate the site of injury and (2) to replenish lost cellular populations. 
Though it is often debated how beneficial the former is, it is well accepted that 
latter may be futile unless therapeutically enhanced. 
OLiGODENDROCYTES: RELEVANCE AND DEVELOPMENT 
Oligodendrocytes in disease 
Of all endogenous responses that involve cell proliferation and migration 
into the SCI epicenter, oligodendrocyte precursor cells (OPCs) are among the 
most relevant and best described (Jones et aI., 2002; Thuret et aI., 2006; 
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McTigue and Tripathi, 2008; Sahni and Kessler, 2010). However, there are 
number of CNS diseases whose pathogenesis includes OL death and 
subsequent failure of endogenous OPCs to lead a complete remyelinative 
response. Aside from SCI, OL loss mediated by acute inflammation followed by 
atrophy of demyelinated axons is classically defined in the progression of 
multiple sclerosis (MS). As current immunomodulatory molecular therapies target 
early MS lesions, these do not provide improvement of chronic/progressive 
phase of disease nor directly facilitate OPC migration, renewal, and/or maturation 
at lesions despite limited remyelination mediated by an endogenous OPC and 
stem cell response (Fancy et aI., 2010; Kremer et aI., 2011). 
Additionally, Periventricular leukomalacia (PVL), which can lead to 
cerebral palsy in affected premature infants, display abnormal myelination 
patterns relative to normal brains. However, this appears to be more specific to 
myelin formation rather than OL death as there was no significant difference in 
0lig2 cell density in PVL affected brains (Billiards et aI., 2008; Fancy et aI., 
2010). Extensive reduction in myelination and OL death is also seen following 
ischemic brain injury and stroke (Zhang and Chopp, 2009). White matter damage 
is also evident in Alzheimer's disease (AD) pathogenesis. Amyloid-~ (an 
extracellular peptide that serves as a pathological hallmark of AD) mediated 
toxicity of OLs is present in AD brains (Xu et aI., 2001; Roth et aI., 2005). 
Furthermore, increasing evidence implicates primary oligodendrogliopathy with 
histopathological features showing OL loss, dysmyelination and subsequent 
axonal loss in another neurodegenerative disease, multiple system atrophy 
3 
(MSA), (Wenning et aL, 2008). The neurodegenerative genetic disorder 
Huntington's disease (HO) also displays pathological hallmarks of myelin 
disruption with loss of cerebral white matter accompanying cortical gray matter 
loss (Fennema-Notestine et aL, 2004). 
Psychiatric disorders such as schizophrenia have considerable OL 
involvement. Increasing evidence suggests OL dysfunction and myelin disruption 
may in fact be the primary alterations in schizophrenia (Takahashi et aL, 2011). 
Additionally, mood disorders such as bipolar disorder demonstrate considerable 
evidence of white matter deficits. These seem to be linked to dysregulation of 
myelin-associated gene expression, particularly neuregulin-1 (NRG1) of which 
genetic polymorph isms have been identified to be associated with the disease 
(Mcintosh et aL, 2009). Overall, there is a large variety of CNS diseases that 
involve OL death and/or dysfunction either as a primary or secondary cause of 
disease typically resulting in axonal myelination abnormalities ultimately followed 
by neurological deficits. 
Oligodendrocytes: Maturation markers 
OPCs are present in both the developing and the adult mammal (Wolswijk 
and Noble, 1989; Noble et aL, 1992; Nishiyama, 1998; Emery, 2010; Trotter et 
aL, 2010). Although the adult CNS maintains a proliferative population of adults 
OPCs that respond to CNS injury and disease, it's reparative/replacement 
response is often insufficient to achieve full remyelination and complete 
functional recovery, as is the case following SCI (Cao et aL, 2005; Totoiu and 
Keirstead, 2005; McTigue and Tripathi, 2008). Therefore, understanding OPC 
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maturation under developmental conditions to improve upon endogenous 
responses will facilitate improvement of adult OPC proliferation and maturation 
following SCI and other CNS injuries and diseases. 
OPC maturation into myelinating OLs is a highly dynamic process with 
each step involving reliable expression of cell surface markers indicative of the 
maturation state (Fig. 1). The sulfatide A2B5 and the chondroitin sulfate 
proteoglycan NG2 (nerve/glial antigen 2) are found to be co-expressed early in 
OPC development and are useful markers indicative of bi-potential OPCs, 
although much debate surrounds NG2+ cells and there lineage commitment or its 
putative classification as fourth major glial cell type (Nicolay et aL, 2007; McTigue 
and Tripathi, 2008; Nishiyama et aL, 2009; Trotter et aL, 2010; Mangin and Gallo, 
2011). This is accompanied by platelet-derived growth factor a-receptor 
(PDGFaR) expression as well as early expression of oligodendroglial lineage 
specific transcription factors 0lig1 and 0lig2 (Nicolay et aL, 2007; Nishiyama et 
aL, 2009). 
As OPC maturation continues, other cell surface sulfatides such as 04 
and 01 are concomitantly synthesized with increased process formation of 
OPCs. It is important to note that 04 serves as a reliable marker for the late 
proliferative OPC whereas 01 is indicative of the non-proliferative, pre-
myelinating, maturing/mature OL (Nicolay et aL, 2007; Nishiyama et aL, 2009; 
Cao et aL, 2010). Finally, the most reliable indicator for the formation of a mature, 
myelinating OL is the synthesis of myelin basic protein (MBP) often observed in 
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membranous sheaths outstretched from a highly arborized OL (Nicolay et aL, 
2007; Trotter et aL, 2010). 
Oligodendrocyte maturation: Permissive factors 
In vivo studies of vertebrate models and in vitro investigations using either 
oligodendroglial cell lines and/or primary OPC cultures have provided great 
insight into the tightly regulated and complex interplay of transcription factors and 
extracellular signals involved in OPC differentiation into a mature, myelinating OL 
(Fig. 1). Early in OPC maturation, expression of basic helix-loop-helix (bHLH) 
transcription factors OLlG1 and OLlG2 is observed and maintained throughout 
OPC differentiation into OLs (Nicolay et aL, 2007). Their function is necessary for 
proper oligodendrogliallineage specification and OL differentiation (Zhou and 
Anderson, 2002; Ligon et aL, 2006; Nishiyama et aL, 2009). Acting synergistically 
with Olig2, a member of the SRY-related HMG-box family of transcription factors, 
Sox10 has been demonstrated to playa pivotal role in OL maturation (Nicolay et 
aL, 2007). In vitro siRNA knockdown of Sox1 0 resulted in decreased 
differentiation of OPCs into MBP+ OLs (Dugas et aL, 2006). Furthermore, 
overexpression of Sox1 0 in embryonic chick spinal cords caused an increase in 
expression of mature OL markers such as MBP and proteolipid protein (PLP) as 
well as Olig2 and Nkx2.2, transcription factors permissive to OL maturation (Liu 
et aL, 2007b). 
Though their mechanisms of action remain uncertain, the homeobox 
proteins Nkx2.2 and Nkx6.2 also playa pivotal role in the formation of mature, 
myelinating OLs (Talbott et aL, 2005; Nicolay et aL, 2007; Cai et aL, 2010). 
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Nkx2.2 knockout mice results in decreased MBP expression in the embryonic 
medulla and reduced PLP expression in the P7 forebrain (Qi et aI., 2001). 
Additionally, Ngn3 knockout mice, which have reduced Nkx2.2 expression in the 
embryonic spinal cord, also have decreased expression of mature OL markers 
PLP and MBP postnatally (Lee et aI., 2003). Nkx6.2 expression is concomitant 
with expression of mature OL markers PLP and MBP (Awatramani et aI., 1997). 
Furthermore, Nkx6.2 is required for normal myelin formation as determined by 
ultrastructural analysis in Nkx6.2 null mice (Southwood et aI., 2004). Nkx6.2 and 
Nkx2.2 expression is tightly coordinated in 01ig2+ OLs as evidenced by early 
Nkx2.2 expression in OPCs followed by its down-regulation and increased 
Nkx6.2 expression in mature OLs in the mouse postnatal spinal cord (Cai et aI., 
2010). Lastly, the extracellular ligand neuronal growth factor Neuregulin-1 
(NRG1) has also been demonstrated to promote OL differentiation in vitro and 
results in hypermyelination following CNS NRG1 overexpression (Calaora et aI., 
2001; Brinkmann et aI., 2008). However, NRG1 appears to be not necessary for 
CNS myelination as other promyelinating factors are likely sufficient (Emery, 
2010). 
Another important mediator of OPC differentiation into mature OLs is the 
thyroid hormone (TH) triiodothyronine (T 3) which increases OL-mediated 
myelination of neurites in spinal cord explants (Park et aI., 2001). Reduced MBP 
and PLP expression is seen in the corpus callosum of hypothyroid animals 
(Ferreira et aI., 2007). Additionally, T 3 treatment of rats that underwent curpizone-
induced demyelination of the corpus callosum showed improved histological 
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outcome relative to saline-treated animals (Franco et aI., 2008). Another 
investigation showed restoration of corpus callosum myelination by diffusion 
tensor magnetic resonance imaging (DT-MRI) in T3 infused mice following 
cuprizone-induced demyelination relative to controls (Harsan et aI., 2008). This 
promotion of ope maturation by TH appears to be mediated by TH receptor 
alpha 1 (TRa1) as TH- treated optic nerve cultures results in decreased 
percentage of 01 + OLs in the absence of TRa1 (Billon et aI., 2002). 
Though mechanisms are still undefined, neuronal activity also appears to 
playa role in OL differentiation (Emery, 2010). Whether by modulation of 
expression of axonal surface ligands or increasing promyelinating factor release 
by astrocytes, both direct and indirect mechanisms have been postulated 
connecting neuronal electrical activity to the promotion of OL maturation (Itoh et 
aI., 1995; Ishibashi et aI., 2006). Additionally, direct stimulation by the 
neurotransmitter glutamate to glutamate responsive opes result in small 
excitatory postsynaptic potentials that regulate ope behavior as well (Barres et 
aI., 1990; Ziskin et aI., 2007; Karadottir et aI., 2008; Emery, 2010). However, 
ope neurotransmitter release onto ope may also be important in maintaining 
the ope pool as in vitro treatment of opes with glutamate resulted in a block in 
rectifier potassium channels and inhibited subsequent OL differentiation (Gallo et 
aI., 1996; Emery, 2010). Though it remains unclear what role neuronal activity 
may have on differing opes populations, neuronal electrical activity nonetheless 
plays a significant role in regulating ope development and maturation. 
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Oligodendrocyte maturation: Inhibitory factors 
In addition to molecular mediators permissive to Ol maturation, there are 
also a number of developmentally identified factors that inhibit OPC 
differentiation into mature, myelinating Ols (Fig. 1). Bone morphogenetic protein 
(BMP) signaling has been well characterized in its role in inhibiting OPC 
maturation and oligodendrogliallineage commitment (Nicolay et aL , 2007). 
Treatment of E16 mixed rat cortical cultures with BMP2 reduced the number of 
04+ OPCs. Treatment with the BMP receptor antagonist Noggin, resulted in the 
opposite effect (Mabie et aI., 1999; Nicolay et aL, 2007). Transgenic mice 
overexpressing BMP4 lead to increased astrocyte lineage commitment rather 
than Ol across the mouse brain (Gomes et aL, 2003). Recently, reactive 
astrocytes from the injured rat spinal cord have been shown to have increased 
BMP expression and this expression counteracted OPC maturation to Ols. 
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Following Noggin treatment, the effect was reversed resulting in increased OPC 
maturation into OLs and reduced astrocyte formation (Wang et aI., 2011). 
Furthermore, active BMP signaling leads to increased expression of helix-
loop-helix (HLH) transcription factors Id2 and Id4 that negatively regulate OPC 
differentiation into mature OLs (Samanta and Kessler, 2004; Nicolay et aI., 
2007). In cultured OPCs, Id2 and Id4 expression results in reduced OPC 
maturation into GaIC+ OLs (Kondo and Raff, 2000; Wang et aI., 2001). As 
reduced levels of the pro-OL transcription factors 0lig1 and 0lig2 are 
concomitant with increased Id2 and Id4, they may playa role in directly reducing 
0lig1 and 0lig2 expression thereby reducing OL maturation (Fu et aI., 2002). 
Furthermore, Id2 and Id4 appear to exert their inhibitory effect on OL formation in 
NG2+/04- OPCs, which is relatively early in the oligodendrogliallineage (Gokhan 
et aI., 2005). Therefore, whether direct or indirect via induced inhibitory 
transcription factor expression, the BMP signaling pathway is a critical 
component in preventing OPC maturation into fully mature OLs. 
In addition to BMP involvement, the single-pass transmembrane protein 
Notch has also been implicated in preventing OL formation (Nicolay et aI., 2007; 
Jessen and Mirsky, 2008). Notch pathway activation with its ligand Jagged 
prevented reduced in vitro differentiation into GaIC+ OLs in rat optic nerve 
isolated OPC cultures (Wang et aI., 1998). In the developing mouse, Cre-
mediated removal of the Notch1 gene resulted in increased number of OPCs and 
their early appearance in the spinal cord. However, the effect is so profound that 
OL differentiation was premature and Notch1 ablated mice had increased OL 
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apoptosis at birth as well as a loss of spatio-temporal regulation of OL 
differentiation throughout the CNS (Genoud et aI., 2002). Additionally, Notch1 
null heterozygous mice displayed increased MBP and PLP expression 
throughout the brain up to 2 weeks postnatally (Givogri et aI., 2002). 
Downstream expression of the transcription factor Hes5 following Notch 
activation is also inhibitory towards OPC maturation (Nicolay et aI., 2007; Li and 
Richardson, 2009; Emery, 2010). Putative Hes5 interaction with pro-OL 
maturation transcription factor Sox1 0 indirectly reduces MBP expression and 
subsequent OPC maturation in an oligodendroglial cell line (Liu et aI., 2006). 
However, the involvement of the Hes family of transcription factors may be more 
complex. Though Hes5 reduces MBP expression, it also reduces overall glial-
restricted precursor (GRP) cell differentiation regardless of cell fate, whereas 
Hes1 preferentially promotes astrocyte differentiation over OLs (Wu et aI., 2003). 
Overall, activation of the Notch signaling pathway likely via reduced expression 
of Hes family members reduces OPC maturation. Nonetheless, as Notch remains 
important in preventing premature OL formation, further understanding of the 
timing of its inhibitory effects is not clearly defined. 
SIGNIFICANCE OF HDAC ACTIVTY 
Histone acetylation and deacetylation 
An important DNA transcriptional regulatory mechanism in eukaryotic cells 
is modulation of chromatin structure. One form of this consists of reversible post-
translational covalent modification of "histone tails", largely on histone 3 (H3) and 
histone 4 (H4) nucleosome subunits (Grunstein, 1997; Cheung et aI., 2000; 
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Haberland et aI., 2009). The resulting alteration of nucleosomal structure 
upstream, downstream or within a specific gene(s), subsequently changes 
transcriptional expression patterns of that gene(s). Of known covalent 
modifications, acetylation and deacetylation of G lysine amino groups in histone 
tail regions of H3 and H4 subunits tightly regulates transcription factor 
accessibility to DNA binding sites that regulate expression of target gene(s) in a 
modulated region (Shahbazian and Grunstein, 2007). Certain DNA binding sites 
become accessible as the addition of an acetyl group to these lysine residues 
results in the neutralization of their positive charge thereby preventing interaction 
between the histone tail and the negatively charged DNA backbone. In contrast, 
deacetylation results in DNA inaccessibility and loss of gene expression 
(Haberland et aI., 2009). 
As histone acetylation depends on the activity of both histone 
acetyltransferases (HATs) and histone deacetylase complexes (HDACs), it is the 
superfamily of HDACs that has received considerable attention due to the 
number of isoforms, the redundancy of their function, and the specificity of their 
targets. Classically, 11 HDAC isoforms have been characterized (excluding the 7 
NAD+ dependent class III HDACs called Sirtuins). Classes I (HDAC1, 2, 3, and 
8), lIa (HDAC4, 5, 7, and 9), lib (HDAC6, and 10), and IV (HDAC11) HDACs are 
zinc-dependent metalloproteins largely involved in deacetylation of acetyl groups 
located on lysine residues of histone tails (Fig. 2). HDAC1 and HDAC2 have 
relatively redundant roles as illustrated in their association with transcriptionally 
repressive multi-subunit complexes (Yang and Seto, 2003). However, HDAC 
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gene and cellular specificity is demonstrated by HDAC3 in its association with an 
entirely different transcriptional complex compared to HDAC1 and HDAC2, by 
HDAC4 and HDAC9 in their tissue expression specificity in the brain, and by 
HDAC6 in its role as the primary mammalian cytoplasmic deacetylase (Zhang et 
aI., 2002; Yang and Seto, 2003; Vega et aI., 2004; Zhang et aI., 2008). 
HDAC inhibitors and their biological effects 
HDAC inhibitors are a varied class of small molecule compounds with a 
high therapy potential that were initially developed for use in anti-cancer 
therapies, though their spectrum of therapeutic potential beyond anti-cancer 
treatment is broadening quickly (Fig. 2) (Abel and Zukin, 2008; Hahnen et aI., 
2008; Bertrand, 2010; Colussi et aI., 2010; Marks, 2010). As mentioned above, 
this modification typically results in heterochromatin modification and 
transcriptional silencing, however, it may also result in increased transcription of 
other genes such as the cell cycle protein p21IWAF1/CIP1 (Richon et aI., 2000; 
Sandor et aI., 2000; Lane and Chabner, 2009; Marks, 2010). As a whole, 
inhibiting HDAC activity results in increased levels of acetylated histone and 
global transcriptional changes that favor expression of genes promoting 
apoptosis and cell cycle arrest (Fig. 3) (Bertrand, 2010; Marks, 2010). 
Additionally, they also playa significant role in post-translational deacetylation of 
other proteins both nuclear and cytosolic as evidenced by stabilization of p53 and 
a-tubulin following HDAC inhibition (HDACi) (Gu and Roeder, 1997; Zhang et aI., 
2003; Lane and Chabner, 2009). Lastly, HDACs have also been shown to be 
important in the regulation of the extrinsic apoptotic pathway as HDACi increased 
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expression of Fas, TNF-a, and TRAIL death receptor proteins (Insinga et aI., 
2005; Nebbioso et aI., 2005; Lane and Chabner, 2009). 
Irregular recruitment HDACs to aberrant fusion proteins were identified in 
acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL) 
(Bolden et aI., 2006; Marks, 2010). Increased expression of largely class I HDAC 
isoforms relative to normal tissues have been reported in many human cancers 
that include gastrointestinal, prostate, non-small cell lung, and breast cancers 
(Bolden et aI., 2006; Marks, 2010). Furthermore, siRNA mediated knockdown of 
individual HDAC isoforms resulted in decreased tumor cell growth and survival in 
a number of human tumor cell lines (Bolden et aI., 2006). These observations 
continued the further development of HDAC inhibitors and spawned the 
extensive work for their use as a treatment against a range of malignancies. 
Primarily five classes of HDACi's have been extensively studied thus far and are 
delineated based on their chemical structure. The short-chain fatty acids 
(aliphatic acids) that include phenyl butyrate and valproic acid (VPA), 
hydroxamates which include trichostatin A (TSA) and the FDA approved 
suberoylanilide hydroxamic acid (SAHA), benzamides such as MS-275, cyclic 
peptides such as depsipeptide (romidepsin), and eletrophilic ketone derivatives 
(Bolden et aI., 2006; Bertrand, 2010; Marks, 2010). Within and between classes, 
there is variability on HDAC isoform inhibitory specificity. VPA is largely a class I 
HDAC inhibitor, TSA and SAHA are pan-HDAC inhibitors, whereas MS-275 is 
inhibitory towards HDAC1 at low concentrations and the remaining class I 
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Figure 2: The HDAC family and 
relevant HDAC inhibitors. Class I 
HDACs include HDACs 1, 2, 3, and 
8. They are specifically inhibited by 
MS-275. Class Iia HDACs include 
HDACs 4, 5, 7, and 9. Though a 
number of Class lIa specific 
inhibitors are in development, 
these are typically inhibited by 
Class 1111 and pan-HDAC inhibitors. 
Class lib includes HDACs 6, and 
10. Due to its unique structure, 
HDAC6 does have a specific 
inhibitor, tubacin . The lone Class 
IV HDAC11 has a largely unknown 
function and can only be inhibited 
by pan-HDAC inhibitors such as 
SAHA and TSA (Bolden et aL , 
2006). 
HDAC mediated chromatin remodeling resulting in transcriptional changes 
is a key regulator of OPC maturation into OLs (Yu et aL, 2010). In vitro and in 
vivo studies indicate that HDAC-mediated histone deacetylation is necessary for 
OL differentiation (Marin-Husstege et aL , 2002; Shen and Casaccia-Bonnefil , 
2008). In fact, HDACi-induced OPC developmental plasticity restricts them from 
a mature OL fate and increases their differential potential to include a neuronal 
lineage (Lyssiotis et aL , 2007). In rat brains, the status of HDAC activity 
determines OPC differentiation into a glial or neuronal fate (Liu et aL , 2007a). 
Furthermore, VPA-mediated HDACi in neonatal rats resulted in hypomyelination 
of the corpus callosum due to reduction of OPC differentiation into mOLs (Shen 
et aL , 2005). In the rat OL-1 oligodendroglia cell line, HDACi by TSA resulted in 
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reduced gene expression of myelin basic protein (MBP) and proteolipid protein 
(PLP), both of which are expressed in mOLs. Moreover, siRNA inhibition of 
HDAC11 mediated deacetylation of H3 and H4 corresponding to the MBP and 
PLP genes prevented OPC differentiation to mature OLs (Liu et aI., 2009). 
Recently, it was demonstrated that VPA-mediated HDACi in cuprizone-
treated adult mice prevented remyelination of the corpus callosum due to 
reduced OPC differentiation (Shen et aI., 2008). Furthermore, HDAC1/2-
mediated disruption of the Wnt signaling pathway are necessary for OL 
maturation (Li and Richardson, 2009; Ye et aI., 2009). These data implicate 
HDACs in a global repressive role in OPC differentiation into mature OLs (Shen 
and Casaccia-Bonnefil, 2008) and suggest that increasing rather than inhibiting 
HDAC activity in OPCs will lead to increased maturation into mOLs and be 
therapeutically applicable in demyelinating disease(s). Recently, increased 
histone acetylation was observed in frontal lobe white matter of chronic MS 
patients relative to non-neurological controls with concomitant increase in 
expression of OL maturation inhibitors suggesting reduced HDAC activity 
efficiency as during MS progression (Pedre et aI., 2011). However, it was also 
recently demonstrated that suberoylanilide hydroxamic acid (SAHA) mediated 
pan-HDACi preserved white matter in ex vivo explants of optic nerve under 
oxygen and glucose deprivation suggesting a putative role HDACi promotion of 
OL survival under ischemic conditions (Baltan et aI., 2011). Overall, these 
studies suggest HDAC activity plays an important role in promoting OPC 
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maturation, however, may have a putative role in improving OL survival under 
certain conditions. 
Role of HDACs in CNS Disease 
Despite concerns over the role of HDACi on OPC maturation, altered 
HDAC activity has been implicated in a number of neurodevelopmental and 
neurodegenerative diseases where HDACi show to be beneficial (Kazantsev and 
Thompson, 2008). Among these, the role of HDACs in the polyglutamine-repeat 
disorders such as Huntington's disease (HD) has been most extensively studied. 
Though a number of cellular perturbations occur in HD, one of the most relevant 
are changes in global histone acetylation patterns and chromatin structure (Butler 
and Bates, 2006). HDAC3 activity increases polyglutamine-mediated toxicity in a 
C. elegans HD model via dysregulation of gene expression when associated with 
co-repressors. HDAC3 targeted siRNA knockdown reduced such toxicity in the 
same animal model (Fischle et aI., 2002; Bates et aI., 2006). Additionally, HDAC5 
nuclear localization is elevated in HD brains, leading to speculation of a role in 
association with HDAC3 (Hoshino et aI., 2003; Butler and Bates, 2006). 
Experimental models of neurodevelopmental diseases such as Fragile X 
syndrome, Friedrich's ataxia, and SMA have also shown improvement with 
HDAC inhibitor treatment (Kazantsev and Thompson, 2008). In vitro models of 
Fragile X syndrome had transcriptional reactivation of the FMR1 gene when 
treated with HDAC inhibitors, a gene silenced in this disease (Chiurazzi et aI., 
1999). HDAC inhibitor treatment of cell-based models for Friedrich's ataxia 
relieved hypoacetylated mediated gene silencing of the frataxin gene that is 
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typically observed in this disease (Herman et aI., 2006; Kazantsevand 
Thompson, 2008). Increased HDAC2 levels are found just upstream of the 
transcriptional start site of the survival motor neuron2 (SMN2) gene- a protein 
insufficiently expressed in SMA (Hirtz et aI., 2005; Kernochan et aI., 2005; Avila 
et aI., 2007). HDACi in brain slices from SMA patients increased SMN2 
expression, resulting in a new putative therapy for SMA currently in clinical trials 
(Hahnen et aI., 2006). 
Lastly, HDACs have been implicated in the development of depression 
and schizophrenia (Tsankova et aI., 2007; Abel and Zukin, 2008). In preliminary 
animal studies, deacetylation mediated by HDAC5 may playa role in anti-
depressant activity (Tsankova et aI., 2006). Likewise, sodium butyrate-mediated 
HDACi in mice resulted in anti- depressant like activity (Schroeder et aI., 2007). 
Most importantly, recovery of learning and memory deficits via dendritic sprouting 
and increased neuronal synapses following HDAC inhibitor treatment were seen 
in mice that displayed a number of cognitive deficits (Fischer et aI., 2007). 
Overall, these data strongly suggest that HDACi may playa role in disease 
process attenuation for a number of neurodevelopmental and psychiatric 
disorders. However, it is important to keep in mind that the development of 
pharmacological HDAC inhibitors was geared towards use as a 
chemotherapeutic agent in conjunction with DNA damaging agents. Therefore, in 
light of the toxicity they display towards transformed cells, an as of yet undefined 
toxicity towards normal cells of the CNS may be present. 
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ROLE OF HDACS IN DNA REPAIR 
HDACs in DNA damage and repair 
Whether originating from exogenous sources such as environmental 
genotoxic agents, ionizing radiation, or chemotherapeutic compounds or from 
endogenous sources ranging from regular DNA replication and repair events, 
replication fork collapse, or cellular metabolic intermediates, DNA is repeatedly 
bombarded by chemicals that can damage it (Hill and Lee, 2010). Therefore, 
repair of DNA damage is one of the most critical physiological functions any cell 
can undertake. This damage may occur in the form of DNA pairing mismatches, 
bulky adducts, base loss, or the formation of single-strand breaks (SSBs) and 
double-strand breaks (DSBs) (Jackson and Bartek, 2009). Depending on the 
type of damage, a wide variety evolutionarily conserved DNA damage response 
(DDR) mechanisms such as nonhomologous end-joining (NHEJ), homologous 
recombination (HR), nucleotide excision repair (NER), and base excision repair 
(BER) exist to counteract potential DNA damage (Lombard et aI., 2005; Jackson 
and Bartek, 2009). However, if these mechanisms fail resulting in improper or 
inefficient DNA repair, then a mutation(s) may occur which could lead to cellular 
transformation or overwhelming accumulating DNA damage will result promoting 
cell death (Lombard et aI., 2005; Jackson and Bartek, 2009). 
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Figure 3: Effects of small molecule-mediated HDACi. Modified diagram 
illustrating how HDAC inhibitors can result in alteration in a large number of 
pathways to elicit death of transformed cells (Marks, 2010). 
Of all of forms of DNA damage, DSBs are regarded as highly toxic and 
potentially most lethal, yet difficult for cells to repair (Abraham and Tibbetts, 
2005; Jackson and Bartek, 2009; Hill and Lee, 2010). Failure to repair DSBs 
results in genomic instability such as chromosomal rearrangements or loss that 
can lead either to cancer or cell death (Jackson and Bartek, 2009; Hill and Lee, 
2010). Cells primarily use either NHEJ of HR mechanisms to repair DSBs 
(Lieber, 2008; San Filippo et aI., 2008; Jackson and Bartek, 2009). DDR in NHEJ 
repair require one, two, or more nuclear serine/threonine protein kinases: DNA-
dependant protein kinase (DNA-PK), Ataxia-telangiectasia mutated (ATM), and 
ATM and Rad3 related (ATR) (Abraham and Tibbetts, 2005; Cimprich and 
Cortez, 2008; Jackson and Bartek, 2009; Hill and Lee, 2010). Following DSB 
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induction, DNA-PK catalytic subunit (DNA-PKcs) is recruited to the site of damage 
and binds the Ku70/Ku80-damaged DNA complex after DSB recognition by 
Ku70/Ku80 (Smith and Jackson, 1999; Hill and Lee, 2010). DSB induction also 
results in Mre11, RAD50, and NBS1 (MRN Complex), which recognizes the site 
of damage and promotes activation of ATM via auto-phosphorylation (Abraham 
and Tibbetts, 2005). Ultimately, DSB activation of DNA-PKcs , ATM, and ATR 
promotes chromatin modification via phosphorylation of serine 139 of histone 
H2A variant H2AX (yH2AX) on chromatin flanking DSB sites. This results in 
recruitment of other DDR proteins that both promote and amplify DSB repair and 
signaling (Jackson and Bartek, 2009). Ultimately, DNA-PKcs, ATM, and ATR 
phosphorylate downstream effectors such as p53, which then subsequently 
promote cell cycle arrest and/or apoptosis (Abraham and Tibbetts, 2005; 
Lombard et aI., 2005; Cimprich and Cortez, 2008; Jackson and Bartek, 2009; Hill 
and Lee, 2010). 
Post-translational modification such as acetylation, phosphorylation, 
methylation, and ubiquitylation, which alter chromatin structure, play an important 
role in DNA repair (Fig. 4) (Misteli and Soutoglou, 2009). More specifically, 
acetylation status in proteins involved in DSB repair and histones as regulated by 
HATs and HDACs are relevant for efficient DSB repair (Misteli and Soutoglou, 
2009; Miller et aI., 2010). HDAC4 in human cell lines was previously shown to co-
localize with p53 binding protein 1 (53bp1) following DSB induction by irradiation 
or etoposide with subsequent knockdown resulting in reduced DNA repair (Kao 
et aI., 2003). Additionally, HDAC mediated deacetylation of Ku70, a component 
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of DNA-PK, is necessary for its DNA binding capability and promotion of DSB 
repair following exogenous DSB induction in prostate cancer cells (Chen et aI., 
2007a). Considerable evidence also demonstrates sensitivity of transformed cell 
lines to combinatorial treatments consisting of both HDAC inhibitors and DNA 
(DSB) damage inducing agents (Karagiannis et aI., 2007; Harikrishnan et aI., 
2008). 
Acetylation of Lys9 and Lys56 of histone H3 (H3K9Ac and H3K56Ac) are 
DNA damage responsive modifications in human cells (Tjeertes et aI., 2009). The 
role of HDAC activity in DSB repair was further explained by demonstrating 
HDAC1 and HDAC2 mediated hypoacetylation of H3K56 in response to DSB 
induction by phleomycin treatment of human cells. Subsequent HDAC1 and 
HDAC2 depletion maintained DNA damage signaling, which may be reflective of 
inefficient DSB repair (Miller et aI., 2010). Furthermore, in Saccharomyces 
cere visiae , HDAC inhibition/ablation counteracts activation of Mec1 (orthologue 
of human ATR) resulting in reduced DSB repair. This is mediated by acetylation 
of the recombination protein Sae2 (orthologue of Human CtBP interacting 
protein, CtIP), following HDACi, which results in Sae2 degradation by promoting 
autophagy (Robert et aI., 2011). However, much remains to be defined, 
particularly in normal CNS cells, in terms of the role HDACs have in maintaining 
genomic stability during typical cell processes and in the presence of 
endogenous and exogenous DNA damaging agents. 
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DNA damage and repair in OLs 
A majority of the studies examining DNA damage in OPCs and OLs 
demonstrate a seemingly enhanced susceptibility to oxidative stress than other 
cells (McTigue and Tripathi, 2008). This is largely attributed to its synthesis of 
large, membranous sheets of myelin which presents the highest metabolic 
demands on any cell of the CNS (Connor and Menzies, 1996; McTigue and 
Tripathi, 2008). Due to OLs increased synthesis of lipids for myelin formation, 
they maintain a relatively large number of peroxisomes which further contribute 
to increased oxidative stress and produce hydrogen peroxide as a byproduct 
(Dewar et aI., 2003; McTigue and Tripathi, 2008). As myelin synthesis is ATP 
dependant, toxic byproducts of ATP synthesis, which also include hydrogen 
peroxide and other reactive oxygen species (ROS) from cellular metabolism, can 
cause OL DNA damage, lead to p53 mediated OL apoptosis, and may even have 
a putative role in MS pathogenesis (Ladiwala et aI., 1999; Uberti et aI., 1999; 
Mouzannar et aI., 2001; Wosik et aI., 2003; McTigue and Tripathi, 2008). Cells 
have mechanisms in place to ensure removal of ROS to prevent cellular damage. 
However, OLs have relatively low basal expression of glutathione, an important 
antioxidative enzyme that reduces ROS to prevent cellular damage, thereby 
making them further susceptible to ROS induced DNA damage (Thorburne and 
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Figure 4: HDAC1/2 involvement in 
the DDR. This model illustrates how 
HDAC1/2 activity is necessary for 
efficient DNA repair. HDAC-mediated 
deacetylaiton is required for NHEJ 
mediated DNA repair. Compounds that 
block HDAC1/2 hyper-acetylation 
causing defective NHEJ repair. As 
NHEJ is one of the primary 
mechanisms for DSB repair, inhibition 
may permit DSBs to persist (Miller et 
al.,2010. 
Though unique sensitivities of OPCs and OLs to oxidative stress has been 
and continues to be studied extensively, one critical component of the cellular 
responses to DNA damage is induction and successful completion of DNA repair. 
These repair mechanisms have been investigated extensively in cell lines, 
invertebrates, and low order vertebrates. However, investigations examining the 
DNA repair capacities of OPCs and OLs are limited. Of particular interest is 
whether cells of the oligodendroglial lineage have a reduced capacity to repair 
DNA, as they may have for ROS scavenging. The first study to demonstrate 
differences in DNA repair capacity between glial cell types was in response to 
alkylating DNA damage. These authors illustrated a four-fold increase in DNA 
repair efficiency following acute exposure to the alkylating agent 06-alkylguanine 
by astrocytes relative to OLs in rat primary astrocyte and OL cultures (LeDoux et 
aI., 1996). The same group further demonstrated differences in mitochondrial 
DNA (mtDNA) repair following exposure to teratogen and alkylating agent 
methylnitrosurea (MNU) was reduced nearly two-fold in OPCs and OLs relative 
to astrocytes resulting in increased OPC and OL apoptosis (Ledoux et aI., 1998). 
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Taken together, these studies suggest a putative reduced capacity for 
OPGs and OLs to respond to increased ROS generation and repair DNA- at least 
in response to DNA alkylating agents- suggesting greater susceptibility to 
oxidative stress and DNA damage relative to other cell types. However, studies 
investigating whether these differences in oligodendroglial lineage cells in 
response to forms of exogenous DNA damaging agents that elicit other types of 
DNA damage (Le. single-strand and double-strand DNA breaks), and whether 
this extends to differences in specific DNA repair mechanisms (Le. base-excision 
repair, non-homologous end joining and/or homologous recombination) remain to 
be defined. 
CICI: SIGNIFICANCE AND PATHOPHYSIOLOGY 
Chemotherapy-induced cognitive impairment (CICI) 
As a phenomenon, GIGI is only recently beginning to be appreciated 
clinically and the mechanisms of which remain largely undefined. Various studies 
have demonstrated that the clinical consequences of GIGI are typically subtle but 
have a broad range of detrimental effects on cognition, including but not limited 
to: attention, concentration, executive function, working and remote memory, and 
processing speed (Fig. 5) (Ahles and Saykin, 2002; Anderson-Hanley et aI., 
2003; Ferguson and Ahles, 2003; Tannock et aI., 2004; Ahles and Saykin, 2007). 
Further complicating understanding of GIGI pathogenesis, it appears only a 
subgroup of chemotherapy patients present with long-term cognitive changes 
(Ahles and Saykin, 2007). However, according to a recently published literature 
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review, CICI incidence varies greatly, with the extensive variability attributed to 
differences in methodology and a paucity of non-conflicting longitudinal studies 
(Argyriou et aI., 2010). Additionally, factors such as emotional distress, anxiety, 
depression, estrogen and testosterone levels, hormonal therapy, and fatigue may 
contribute to reduced cognitive function, however, in recent studies 
demonstrating CICI these psychological factors are taken into consideration 
(Ahles and Saykin, 2007; Argyriou et aI., 2010). 
Objective visualization to uncover pathology secondary to chemotherapy 
that may contribute to CICI onset involves magnetic resonance imaging (MRI) 
and positron emission tomography (PET) studies (Ahles and Saykin, 2007). 
Decreased volume in brain structures relevant for various cognitive functions as 
well as reduced integrity of white matter tracts as determined by MRI following 
chemotherapy have been associated with cognitive decline (Stemmer et aI., 
1994; Saykin et aI., 2003; Ahles and Saykin, 2007). Longitudinal studies in breast 
cancer patients demonstrated decreased cognitive function in 61 % of study 
participants who received adjuvant chemotherapy and altered 
neuropsychological testing in 33% of women who received doxorubicin/ 
cyclophosphamide treatment (Jansen et aI., 2008; Argyriou et aI., 2010). 
Additional studies assessing cognitive function in long-term breast cancer 
survivors have found reduced gray and white matter volumes across multiple 
brain regions including the prefrontal cortex, hippocampus, parahippocampal 
gyrus and precuneus, and related cognitive decline to reduction of normal 
appearing white matter in the genu of the corpus callosum (lnagaki et aI., 2007; 
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Abraham et aL , 2008; Argyriou et aL , 2010). Furthermore, attenuated cellular 
metabolism in the frontal cortex, basal ganglia, and cerebellum following 
chemotherapy as determined by PET scan were observed in another study of 
chemotherapy treated breast cancer survivors. The authors further demonstrated 
a correlation of altered short-term memory test performance with glucose 
metabolism in the inferior frontal gyrus (Argyriou et aL , 2010). 
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Figure 5: Brain regions implicated in CICI pathogenesis (Argyriou et aL , 
2010). 
Chemotherapeutic agents such as carmustine and methotrxate have 
previously been demonstrated to cause leukoencephalopathy, which have 
characteristics of periventricular white matter lesions and cortical atrophy 
(Dietrich et aL , 2008). In fact, several month delayed onset of white matter 
abnormalities are present in 70% of patients treated with high-dose 
chemotherapy (Stemmer et aL , 1994; Brown et aL , 1998; Dietrich et aL , 2008). 
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Lastly, delayed leukoencephalopathy syndrome as detected by MRI indicated 
significant white matter damage in patients largely receiving methotraxate, 5-
flurouracil, carmofur, and capecitabine chemotherapy treatment (Dietrich et aI., 
2008). Therefore, extensive imaging studies accompanied by testing of cognitive 
function of patients receiving a variety of chemotherapeutic treatment not only 
uncover putative pathological findings in CICI development, but also 
demonstrates the need to further our understanding of the mechanisms 
underlying CICI pathogenesis as the number of chemotherapeutic agents, and 
the number of cancer survivors, continue to increase. 
Chemotherapeutic Agents: Crossing the Blood-Brain Barrier 
In order for the systemically administered chemotherapeutic agents to be 
toxic to the CNS, they, or there byproducts, must be blood-brain barrier (BBB) 
penetrable (Ahles and Saykin, 2007). Although a majority of chemotherapeutic 
drugs do not pass through the BBB at levels that may be effective against CNS 
tumors, levels as low as those having little efficacy against a peripheral tumor 
itself may still be found in the CNS and be sufficiently toxic towards non-
transformed CNS cells (Fig. 6). A recent study demonstrated cisplatin, cytosine 
arabinoside, and carmustine resulted in increased cell death in multiple regions 
of mouse brains, including the hippocampus and the corpus callosum, at drug 
levels lower than needed for efficacious tumor cell death (Ahles and Saykin, 
2007; Dietrich et aI., 2008). Furthermore, genetic polymorphisms in genes 
encoding BBB drug transporters may result in increased concentration of 
chemotherapeutic drugs in the CNS (Ahles and Saykin, 2007). Individuals who 
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are homozygous for the C allele in the multidrug resistance 1 (MDR1) gene 
(C3435T in exon 26) which encodes P-glycoprotein (P-gp), a common substrate 
for many chemotherapeutic drugs and has a protective role in transporting toxic 
substances out of cells, have shown reduced plasma concentrations of various 
drugs relative to people homozygous for the T allele (Ahles and Saykin, 2007). 
Additionally, alterations in blood flow dynamics may promote increased 
passage of chemotherapeutic agents into CNS parenchyma. Chemotherapetuic 
agents have been shown to reduce cerebral blood flow and may cause vascular 
toxicity themselves (Seigers and Fardell, 2011). Though intended to improve 
drug delivery to the brain, cerebral hypoperfusion was recently shown to be 
effective in increasing intraarterial deposition of the already lipid soluble drug 
carmustine into brain tissue (Joshi et aI., 2008). However, such change in blood 
flow dynamics during chemotherapeutic treatment, whether they are an 
intentional manipulation of CNS blood flow or not, may be sufficient to expose 
healthy parts of the brain and spinal cord to increased levels of chemotherapeutic 
agents. Furthermore, vascular injury perhaps following ischemic or hemorrhagic 
stroke occurring as adverse effects of chemotherapeutic treatment (as has 
previously described with cisplatin) or due to co-morbidities in patients receiving 
chemotherapy could result in an unexpected increase in drug exposure to normal 
cells of the CNS as the BBB would likely be compromised (Meattini et aI., 2010). 
Therefore, when determining the CNS toxicity potential of any chemotherapeutic 
agent, it is important to not only assess the BBB penetrability properties of the 
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drug itself but to also consider changes in vascular flow, injury, and the integrity 
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CICI pathogenesis secondary to DNA damage 
Figure 6: Putative 
mechanisms involved in 
CICI pathogenesis. 
(A) Chemotherapeutic agents 
that penetrate the BBB in 
small amounts, (B) directly or 
indirectly cause DNA 
damage, (C) result in 
inflammation, and (D) reduce 
hormone levels may cause 
significant CNS toxicity and 
cognitive decline, (E) 
particularly in those of may 
have a genetic predisposition 
(Ahles and Saykin, 2007). 
Chemotherapy-mediated DNA damage of transformed cells is one of 
many mechanisms involved in transformed cell death but may be the most 
relevant one relative to CICI pathogenesis (Fig. 6). Anti-metabolites are a class 
of chemotherapeutic agents that disturb DNA and RNA replication and formation, 
respectively, by inhibiting the synthesis of new nucleic acids (Seigers and 
Fardell, 2011). In relation to CICI pathogenesis and subsequent clinical 
presentation, 5-fluorouracil (5-FU) and methotrexate (MTX) are the most 
extensively studied within this class of compounds (Janelsins et aI., 2011; 
Seigers and Fardell, 2011). Rats displayed reduced Morris water maze (MWM) 
learning, novel object recognition (NOR), and operant response learning 
following MTX treatment, all indicators of increased cognitive impairment 
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(Seigers et aI., 2008). 5-FU treatment showed similar results of impaired object 
recognition placement and retrieval of a learned operant response, all of which is 
again suggestive of increased cognitive impairment (Seigers and Fardell, 2011). 
MTX has also demonstrated to have direct neurobiological affects that may 
account for the observed cognitive deficits. Increased oxidative damage, reduced 
neurogenesis, and increased neurotoxic apoptosis occur following MTX 
treatment in animals (Seigers et aI., 2009; Janelsins et aI., 2011). Lastly, both 
MTX and 5-FU systemic administration alone induced CNS toxicity is not limited 
to neuronal effects as significant white matter damage is also observed (Han et 
aI., 2008; Janelsins et aI., 2011; Seigers and Fardell, 2011). 
Another class of chemotherapeutic drugs, the DNA alkylating agents, 
which damage DNA by directly adding an alkyl group to guanine, have also 
demonstrated to induce an appreciable amount of cognitive deficits. 
Cyclophosphamide (CYP) is one of the most extensively studied and displays 
cognitive impairment in a number of animal studies. In rats, whether alone or in 
combination with doxorubicin, both passive avoidance task learning and 
contextual fear conditioning were impaired following treatment (Seigers and 
Fardell, 2011). Following CYP treatment in mice, memory retention, NOR, and 
passive avoidance task learning were all effected suggesting development of 
cognitive deficits (Seigers and Fardell, 2011). Impariment of these tasks might be 
explained by increased oxidative stress following CYP and doxorubicin 
administration as antioxidant treatment with N-acetyl cysteine improved cognitive 
function (Konat et aI., 2008; Seigers and Fardell, 2011). Furthermore, CYP 
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treatment reduced hippocampal neurogenesis in mice that displayed reduced 
memory retention (Yang et aI., 2010). Lastly, thioTEPA, another 
chemotherapeutic agent in this class, displayed a long term dose-dependent 
reduction in hippocampal cell proliferation with accompanying memory deficits 
further implicating alkylating agent mediated neurotoxicity in CICI pathogenesis. 
Cisplatin, a platinum containing chemotherapeutic agent that acts as an 
alkylating agent (without alkyl group addition), resulting in DNA crosslinking, and 
promoting apoptosis, has also been demonstrated to cause cognitive impairment 
and neurotoxicity (Seigers and Fardell, 2011). Oxaliplatin, an analogue of 
cisplatin used in the treatment of advanced colorectal cancer, display reduced 
NOR and spatial reference memory. When given in combination with 5-FU, 
performance on these tasks worsens (Seigers and Fardell, 2011). Additionally, 
cisplatin resulted in in vitro cytotoxicity of cerebellar granule neurons, though 
astrocytes appear to be not as susceptible (Wick et aI., 2004). Cisplatin treatment 
in the developing rat brain resulted in lesion formation in multiple brain regions 
including the cortex and the hippocampus. Morphologically analysis suggested 
neurons were undergoing excitotoxicity with subsequent active cell death (Rzeski 
et aI., 2004). Additionally, cisplatin treatment in rats showed greater toxicity in 
CNS proliferating cells and mature OLs demonstrating increased cell death in the 
corpus callosum in addition to relevant cancer cell lines (Dietrich et aI., 2006). 
Overall, studies involving these agents suggest direct a connection between 
reduced neurogenesis, and OL and neuronal death in a range of brain regions 
32 
with behavioral manifestations suggestive of cognitive decline, such as memory 
deficits, following treatment. 
Finally, inhibitors of DNA topoisomerase I and II causing the formation of 
single-strand breaks (SSB) and double strand breaks (DSB) in the DNA structure 
resulting in cycle arrest and/or apoptosis, has been shown to display 
neurotoxicity as well. DNA topoisomerases are involved in reducing torsional 
stress following unwinding of the DNA double helix during DNA replication and 
transcription (Seigers and Fardell, 2011). As the relaxation of torsional stress 
involves making DNA breaks with subsequent re-ligation, small molecule 
mediated topoisomerase stabilization prevents DNA reannealing resulting in DNA 
SSBs and DSBs. Primary cerebellar granule neurons demonstrated a 10-fold 
higher susceptibility to topotecan, a derivative of the topoisomerase I inhibitor 
camptothecin, relative to glioma cells (Wick et aI., 2004). In a phase II clinical trial 
using a combinatorial treatment of gemcitabine with etoposide, a topoisomerase 
II inhibitor, caused a significant increase in cognitive impairment relative to 
another treatment group not receiving etoposide (Mok et aI., 2005). Lastly, in 
addition to DNA DSB formation with subsequent neuronal apoptosis, etoposide 
mediated nucleolar stress resulted in non-apoptotic neurotoxicity of primary rat 
cortical neurons potentially providing a critical mechanistic clue to the clinical 
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Figure 7: Hypothesized model for HDACi therapeutic benefit on OPCs. (A) 
In response to stressors (trauma, ischemia, hypoxia, etc.) HDAC activity may 
contribute to increased OPC death. This in turn results in an attenuated 
remyelination response resulting in a greater number of spared unmyelinated 
axons. (8) Small molecule-mediated HDACi will reduce HDAC activity causing 
increased expression of survival factors promoting OPC survival and resulting in 
an im roved rem ination nse. 
SUMMARY 
Putative Model 
Despite concerns regarding inhibition of OPC maturation following HDACi, 
we wanted to determine whether transient treatment of OPCs with a small 
molecule HDAC inhibitor may be a viable therapy, as has been suggested in 
other CNS disease models and cell types, to promote OPC survival in acutely 
stressed conditions (Fig. 7). To investigate this, we developed and characterized 
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a purified postnatal mouse cortical OPC primary culture as discussed in chapter 
two. As presented in chapter three however, rather than cell survival, extensive 
cell death was observed acutely following treatment in vitro, as well as in parallel 
in vivo studies. Lastly in chapter four it is demonstrated that putative mechanisms 
involved in this OPC susceptibility to HDACi-mediated cytotoxicity, such as DNA 
damage, are similar to those already described in transformed cell lines. 
Overall, these results suggest our original hypothesis of a therapeutic effect on 
OPC survival following small molecule mediated HDACi in the presence of other 
stressors was incorrect. Rather, HDACi is detrimental to OPC survival 
demonstrating that great caution must be taken in the future clinical use and 
development of HDAC inhibitors due to potential effects of OPC toxicity, including 
but not limited to DNA damage induction. Subsequent dysmyelination may occur 
that may lead to cognitive deficits similar to those described in CICI pathogenesis 
following treatment with other well investigated chemotherapeutic agents. 
35 
CHAPTER 2 
ISOLATION OF CORTICALLY DERIVED MOUSE OLIGODENDROCYTE 
PRECURSOR CELLS 
INTRODUCTION 
The developing mammal maintains an extensive population of CNS 
progenitor cells maturing along the oligodendroglial lineage to yield fully 
differentiated Ols that myelinate all axons within the CNS (Wolswijk and Noble, 
1989; Noble et aI., 1992). Of these progenitor populations, OPCs provide the 
largest source of maturing Ols, though a significant OPC subpopulation avoids 
differentiation maintaining their proliferative state (Nishiyama et aI., 2009; Trotter 
et aI., 2010). Isolation and subsequent in vitro study of OPCs both in the 
developing and adult mammal offers critical insights into putative disease and 
injury mechanisms involved in demyelinating disease states such as multiple 
sclerosis and CNS white matter infarctions as observed in ischemic stroke 
(Nishiyama, 1998). Furthermore, OPC engrafiment into the injured CNS to 
replenish lost Ols continues to offer promise as a cell therapeutic method for the 
treatment of spinal cord injury (Cao et aI., 2010). 
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A variety of cell surface markers indicate the state of ope maturation in 
the oligodendroglial lineage. A2B5, a cell surface glycoside, and NG2, a 
chondroitin sulfate proteoglycan, are indicative of the immature ope population 
(Nishiyama et aI., 2009). However, NG2+ cells may not be specific to cell 
progenitors committed to an Ol fate. In addition to having recently described 
synaptic associations to neurons, they also maintain the capacity to terminally 
differentiate into astrocytes in addition to Ols (McTigue and Tripathi, 2008; 
Emery, 2010). 04, a later stage Ope-specific galactocereboside found on the 
cell surface, contrasts A2B5 and NG2 in serving as a more reliable marker for 
opes committed to an oligodendroglial fate (Nishiyama, 1998; Nicolay et aI., 
2007; Nishiyama et aI., 2009; Trotter et aI., 2010).01, another oligodendroglial 
lineage specific galactocereboside expressed on the cell surface of pre-
myelinating Ols is indicative of an ope that no longer maintains its proliferative 
potential but is transitioning to the terminally differentiated OL. As the pre-
myelinating Ol matures into the myelinating Ol, the presence of the 01 cell 
surface antigen is accompanied by myelin basic protein (MBP) expression, one 
of the primary protein constituents of myelin and a marker for the mature 
myelinating Ol (Nicolay et aI., 2007; Trotter et aI., 2010). 
Numerous oligodendroglia I cell lines have been developed for the study of 
Ol function (Lin et aI., 2006; Mock et aI., 2006; Pringproa et aI., 2008). However, 
there is considerable variability between these cell lines largely depending on the 
source (i.e. chemically induced rodent tumors or spontaneous human tumors), 
isolation method, and growth conditions. Often times, these lines maintain 
37 
considerable proliferative potential, even once engrafted (a hallmark of their 
potential tumorigenicity), and may prove difficult for induction of differentiation 
(Lin et aI., 2006; Pringproa et aI., 2008). OPC cultures derived from the formation 
of neurospheres or oligospheres yield similar variability in genetic and phenotypic 
makeup resulting in considerable departure from their in vivo counterparts (Chen 
et aI., 2007b; Zhao et aI., 2010). Furthermore, with passage, subtle cellular 
changes occur resulting in a molecularly different cell type than what was 
originally isolated (Lin et aI., 2006). Lastly, nearly all existing primary OPC 
cultures from rodent models rely on more premature markers A2B5 and NG2 
which may not have as extensive oligodendrogliallineage commitment (Larsen 
and Yong, 2004; Hamanoue et aI., 2009). Primary OPC cultures will be better 
served using a later stage marker than is more limited to the oligodendroglia I 
lineage but still maintain their proliferative capacity. 
To address these concerns in existing OPC isolation methods, we 
developed and characterized a reliable and reproducible primary culture of 
cortically-derived OPCs from mouse pups. We limited the scope of this 
characterization to no more than a single passage following each OPC isolation 
to limit the potential of genetic and phenotypic drift often observed with additional 
passages. Furthermore, we used the OPC cell surface antigen 04, meeting the 
criteria of isolating OPCs that are proliferative and have greater commitment to 
OL differentiation than the oligopotent A2B5 and NG2 progenitor cells. Though 
differentiation of these isolated OPCs in vitro still yields both OLs and astrocytes, 
isolated mouse OPCI DRG co-cultures results in extensive OPC maturation with 
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nearly complete absence of astrocytes. Overall this method will facilitate the 
continued study of OPC differentiation and OL function and provide in vitro 
findings that will be better recapitulated in vivo. 
MATERIALS AND METHODS 
Animals 
E12-E15 time pregnant C57BI/6 mice and E15 Sprague-Dawley rats were 
purchased from Charles River Laboratories (Wilmington, MA). All animal 
procedures were performed according to the guidelines of University of Louisville 
Institutional Animal Care and Use Committee protocols and the National 
Institutes of Health. 
Preparation for mouse ope isolation 
Prior to OPC isolation, 13.5 IJI of 50 mM p-mercaptoethanol was combined 
(Sigma, St. Louis, MO) to 10 ml of Solution 2 from the Neural Tissue Dissociation 
Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). MACS Buffer was prepared 
by adding 5% bovine serum albumin (BSA), 0.5 M EDTA, and 5 IJg/ml insulin in 
Dulbecco's phosphate buffered saline supplemented with 1 gIL glucose (all from 
Sigma). OPC-A media was prepared by adding 2.1 gIL NaHC03 (Sigma) to 
dissolved DMEM-F12 without HEPES powder (Invitrogen, Carlsbad, CA). N2 
supplement (1%), B27 supplement (2%), Penicillin/Streptomycin (1%, all from 
Invitrogen), BSA (0.01 %, Sigma), 40 ng/ml fibroblast growth factor 2 (FGF2, 
Millipore, Billerica, MA), and 20 ng/ml platelet-derived growth factor-aa (PDGFaa, 
Sigma) was added to the previously prepared DMEM-F12. Differentiation media 
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components included N2 supplement (1 %), B27 supplement (2%), 
Penicillin/Streptomycin (1 %), 50 IJg/ml insulin, and 40 ng/ml triiodo-thyronine (T3, 
Sigma) in DMEM/F12. Differentiation media was supplemented with 1 ng/ml 
ciliary neurotrophic factor (CNTF, Sigma) where appropriate. Where described, 
"pre-equilibration" refers to cell media incubated for a minimum of 30 minutes in 
37°C, 5% CO2 prior to use. 
Dissection of mouse cortices 
Whole mouse brains were harvested from ice-anesthetized postnatal day 
5-7 mouse pups by decapitation following loss of reflexive movement 
(approximately 5-8 minutes in ice). The skin and skull were cut along the midline 
and reflected to expose the brain. The brain was then removed and placed in a 
pre-chilled Petri-dish with sufficient volume of HBSS without Ca+ and Mg+ 
(Lonza, Walkersville, MD) to submerge the brain. Afterwards, the cerebellum, 
brain stem, olfactory bulbs, and olfactory tracts were removed, and followed by 
careful dissection of the meninges from the remaining cortex. This was repeated 
for as many brains as desired for a particular isolation. Finally, dissected cortices 
were transferred into a pre-weighed dish with pre-chilled HBSS without Ca + and 
Mg+ and all cortices weighed. 
Tissue dissociation of mouse cortices 
Using the Neural Tissue Dissociation Kit (Miltenyi Biotec), an appropriate 
volume of Enzyme Mix 1 corresponding to the cortical tissue mass was 
prepared. For every 400 mg of tissue, 50 IJI of Solution 1 was added to 1.9 ml of 
pre-made Solution 2 with BME. This was briefly vortexed and then preheated in 
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a 37°C water bath for 10 minutes before use. As Enzyme Mix 1 was heating, 3 
Pasteur pipettes were fire polished with decreasing tip diameters and set aside 
for later use. Brains were transferred to a 0.5 ml drop of HBSS in the middle of a 
fresh 10 cm dish. Cortices were diced thoroughly (1 mm3 pieces) with a razor 
blade, then 5-6 ml of HBSS was added then tissue pippetted into a 15 ml conical 
tube. The dish was rinsed well with fresh HBSS to collect any remaining tissue 
and added into the 15 ml conical tube. Tissue was centrifuged at 300 x 9 for 2 
minutes at room temperature (RT). Supernatant was then carefully aspirated, 
followed by addition of the pre-heated Enzyme Mix 1 to the pellet, and then 
gently mixed taking care to avoid air bubbles. Tissue was then incubated for 15 
minutes in the 37°C water bath, inverting the tube several times every 5 minutes 
to resuspend settled cells. During incubation, an appropriate volume of Enzyme 
Mix 2 was prepared. For every 400 mg of tissue, 20 IJI of Solution 3 was added 
to 10 IJI of Solution 4. Once the incubation was complete, Enzyme Mix 2 was 
added to the tube containing the tissue. This was inverted gently to mix and then 
slowly triturated approximately 15 times using the widest fire-polished pipette 
again taking care to avoid air bubbles. This was then incubated in a water bath 
for 10 minutes, inverting several times after 5 minutes of incubation. Tissue was 
slowly triturated approximately 15-20 times each using the remaining two fire-
polished pipettes in decreasing diameter. Then tissue was incubated again in a 
water bath for 10 minutes, inverting several times after 5 minutes of incubation. 
During the incubation, a 40 IJm cell strainer was pre-wetted with 5 ml DPBS into 
a 50 ml conical tube. DPBS was then aspirated from the tube and following the 
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tissue incubation, the suspension was slowly decanted through the strainer. The 
15 ml tube with the tissue was rinsed with 10 ml of HBSS with Ga + and Mg + 
(Invitrogen) and added this to the strainer. The cell suspension was centrifuged 
at 300 x g for 10 minutes at RT. The supernatant was gently aspirated, leaving 
approximately 2-5ml of supernatant in the tube, and cells were washed with 10 
ml of HBSS with Ga+ and Mg+ and centrifuged 300 x g for 10 minutes at RT. The 
supernatant was aspirated and the pellet gently resuspended in 5 ml MAGS 
buffer. A small aliquot was then removed for a cell count and the cell suspension 
transferred to a 15 ml tube and centrifuged 300 x g for 5 minutes. During 
centrifugation, the total number of live cells were counted by Trypan Blue 
visualization. Depending on the number of brains dissected, counts ranged from 
1.0 - 5.0 x 107 cells with a cell viability range of 85-95%. 
Magnetic cell sorting (MACS) for OPC enrichment 
Following the total cell count, the supernatant was gently aspirated and rat 
anti-mouse IgM magnetic beads (10% v/v in MAGS Buffer, Miltenyi Biotec) were 
added to the cells. The pellet was then gently resuspended and incubated for 15 
minutes at 4°G with gentle shaking. As cells may settle, cells were mixed by 
tapping the tube every 5 minutes. Following incubation, cells were resuspended 
in 5 ml MAGS buffer and centrifuged at 300 x g for 5 minutes at RT. During 
centrifugation, we set up a MAGS MS column (Miltenyi Biotec) on a MAGS 
magnetic stand (Miltenyi Biotec) and equilibrated the column with 0.5 ml of 
MAGS buffer. A 15 ml conical tube was then positioned below the column to 
collect the flow-through. Following the spin, cells were resuspended in 0.5 ml 
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MACS buffer, transferred to the column, and the column was washed four times 
with 0.5 ml MACS buffer. The initial flow through and all subsequent washes 
were collected in a single 15 ml tube and centrifuged at 300 x 9 for 5 minutes. 
Following centrifugation, the cell pellet was resuspended in 400 1-11 of diluted 04 
antibody. This was incubated 5-10 minutes at 4°C with gentle shaking and mixed 
once by tapping. The cell suspension was then washed two times by adding 5 ml 
MACS buffer followed by centrifugation at 300 x 9 for 5 minutes. During 
centrifugation, an additional MACS rat anti-mouse IgM beads mix was prepared 
based on the total cell count. For every 1 x 107 cells, 20 1-11 MACS beads were 
mixed with 180 1-11 MACS Buffer. Following centrifugation, cells were resuspended 
in the second MACS beads mix and incubated 15 minutes at 4°C with gentle 
shaking. If cells settled, the suspension was mixed by tapping every 5 minutes. 
Afterwards, cells were resuspended in 5 ml MACS buffer and centrifuged 300 x 9 
for 5 minutes. During centrifugation, another MACS column was equilibrated with 
0.5 ml MACS buffer as described above. The pellet was resuspended in 0.5 ml 
MACS buffer and added to the column, washed four times with 0.5ml MACS 
buffer, and bound cells eluted in 1 ml MACS buffer into a fresh 15 ml tube. Air 
bubbles were unavoidable during this step; however, we minimized their contact 
with the cell suspension at the bottom of the tube. A fresh column was quickly 
equilibrated, eluted cells added, the column washed four times with 0.5 ml MACS 
buffer, and cells eluted into a fresh 15 ml tube in 1 ml pre-equilibrated OPC-A 
medium. 1 ml of additional medium was added to this cell suspension and mixed 
thoroughly. Cells were counted, plated in a PDLllaminin-coated 10 cm tissue 
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culture dish, and incubated in 37°C, 5% CO2. Approximately 9,000-15,000 
cells/cm2 were plated for a successful OPC isolation. 
OPC expansion, differentiation, and OPC/DRG co-culture 
The day following OPC isolation, all medium was removed from the plate 
and replaced with fresh, pre-equilibrated OPC-A media. For subsequent daily 
medium changes, % medium was removed from the culture dish and replaced 
with pre-equilibrated OPC-A media. Cells were then ready to passage within 6-9 
days, depending on plating density and proliferative rate. Passaging was 
performed using Accutase® (Sigma) according to the manufacturer's 
instructions. Briefly, media was removed and plated OPCs were rinsed once with 
DPBS. Immediately afterwards, Accutase® was added (approximately 1 ml/10 
cm2) and incubated in 37°C for 10 minutes. Following incubation, about half of 
the Accutase® containing cells was removed and the plate rinsed 2-3 times to 
remove remaining adherent cells. The cell suspension was transferred to a sterile 
tube, the plate washed with 3-4 ml of OPC-A media, and added to the cell 
suspension. Immediately cells were centrifuged 300 x 9 for 5 minutes at RT. The 
supernatant was gently aspirated and cells resuspended in 2 ml of pre-
equilibrated OPC-A media. Ideal plating densities of P1 OPCs typically ranged 
between 7,500-10,000 cells/cm2. Following passage, OPCs were fed with % 
media change with pre-equilibrated mOPC-A every other day until used for 
experimentation. 
For OPC differentiation, P1 OPCs were allowed to expand in OPC-A 
media for 3-5 days then replaced with pre-equilibrated Differentiation media. 
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Depending on desired state of maturation, OPCs were allowed to differentiate in 
Differentiation media for 3-10 days with Y:z media change with pre-equilibrated 
Differentiation media every other day. For OPC/DRG co-cultures, DRGs were 
isolated from E15 Sprague-Dawley rat embryos as previously described (Plant et 
aI., 2002; Cheng et aI., 2007; Cao et aI., 2010). Following isolation, DRGs were 
plated 5,000 cells/cm2and maintained on collagen coated coverslips in NB1 
neurobasal medium to permit neurite outgrowth for at least three weeks and no 
more than four weeks prior to seeding with P1 OPCs. Once seeded, OPC/DRG 
co-cultures were maintained 7-14 days in Differentiation media without 
Penicillin/Streptomycin to permit OPC maturation with Y:z media change every 
other day using pre-equilibrated media. 
Immunocytochemical analyses 
Immunocytochemical analysis of OPC cultures in OPC-A and 
Differentiation media and OPC/DRG co-cultures were done as previously 
described (Cao et aI., 2010). Briefly, cells were washed in DPBS and then 
incubated with the respective hybridoma supernatants for 45 minutes at 4°C. 
Afterwards, cells were fixed in 4% paraformaldehyde at room temperature for 10 
minutes. Cells were blocked and incubated overnight with additional non-
hybridoma primary antibodies in 4°C with 10% normal donkey serum (NOS, 
Jackson ImmunoResearch, West Grove, PA), 0.5% BSA (Sigma), and 0.1 % 
Triton X-1 00 in DPBS. The following day, cells were incubated in secondary 
antibody at room temperature for one hour in 5% NOS, 0.5% BSA, and 0.1 % 
Triton X-100 in DPBS. Antibodies used include mouse anti-A2B5 IgM, mouse 
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anti-04 IgM, and mouse anti-01 IgM (hybridoma derived, 70% v/v in 20% DPBS, 
and 10% NDS), rabbit anti-NG2 (1 :500, Millipore), rabbit antH3111-tubulin (1 :2000, 
Covance, Princeton, NJ), rat anti-MBP (1:100, Millipore), rabbit anti-GFAP 
(1 :500, Dako, Glostrup, Denmark), and rabbit anti-Map2 (1 :100, Sigma). Cells 
were incubated with FITC, Texas Red, and Rhodamine Red conjugated F(ab'h 
fragment antibodies (Jackson Immunoresearch). Negative controls for antibody 
staining included the appropriate species-specific non-immune IgG or IgM 
antibodies substituted for the primary antibodies. 10X and 20X photomicrographs 
were captured with a Nikon TiE 300 inverted microscope equipped with a DXM-
1200C coded digital camera and NIS Elements software (Nikon, Melville, NY). All 
quantitative data are presented as means +/- S.D. 
RESULTS 
ope enrichment 
Using postnatal day 5-7 mouse cortices, we achieve a yield of 
approximately 3. 7x1 05 cortical OPCs/brain (Fig. 8). In contrast to the previous 
adult rat OPC spinal cord primary culture developed in our lab, expanding the 
04+ OPC population proved difficult. From 3 days post plating, enriched OPCs 
are phase bright with typical bipolar morphology (Fig. 9A). A large portion of the 
isolated OPC population at PO is 04+ (Fig. 9A-C). Furthermore, at P1 our primary 
culture remained almost entirely A2B5+ and NG2+ (Fig. 9D-F), demonstrating an 
expanded population of enriched OPCs positive for early OPC markers. 
Furthermore, all cells at PO and P1 were GFAP (Fig. 9B-C) and ~-III tubulin (data 
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not shown) negative indicating enrichment of a cell population devoid of astrocyte 
and neuronal contamination, respectively. 
ope Isolation Figure 8: Cortical OPC yield 
Yield (Opes/Brain) I 3.68 x 105 +/. 9.17 x 104 from mouse P5-P7 pups. 
Following passage, despite being A2B5+ and NG2+, the percentage of 04+ 
cells declined from approximately 80% just prior to passage (data not shown) to 
just under 50% of the total cell population (Fig. 10). Nonetheless, over 90% of all 
cells remained both A2B5+ and NG2+ with continued expansion (Fig. 10). Further 
quantification of revealed that the isolated opes remained immature as they 
were not 01 + OLs and did not have any GFAP+ astrocytes (Fig. 10). These data 
suggest with continued expansion in vitro 04 surface expression declines but 
other markers indicative of ope phenotypes remain positive indicating 
maintenance of the ope phenotype. 
Figure 9: Isolated cells express multiple OPC specific surface markers. (A) 
Phase contrast image of opes 3 days following isolation showing typical ope 
mo and isolated cells are 04+ and GFAP- 10X. 04+ opes form 
47 
multiple processes following plating, scale bar 20 IJm (O-F) Following passage, 
P1 OPCs co-ex ress earl OPC surface markers A2B5 and NG2, 20X. 
ope differentiation 
Mouse cortically derived OPC differentiation may commit to either GFAP+ 
astrocytes or OLs (Fig. 11). OPC differentiation from 4 to 6 days in the presence 
of serum and the absence of POGFaa and FGF2 leads to astrocyte 
differentiation as evidenced by nearly 100% GFAP+ immunoreactivity with 
minimal 04 and 01 immunoreactivity (data not shown). 
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Figure 10: P1 ope cell counts 
show an enriched population of 
opes. Approximately 50% of P1 
OPCs are 04+ (49.05 +/- 6.08%) and 
over 90% of cells are both NG2+ 
(90.14 +/- 6.05%) and A2B5+ (94.55 
+/- 2.77%). Cells were not 01 and 
GFAP immunopositive indicating an 
enriched population of expanding 
OPCs. N=3, +/- SO. 
When OPC growth media is replaced by low serum media without 
POGFaa and FGF2 but in the presence of thyroid hormone (T3) differentiation 
into a mixed glial population occurs. There is reduced number of cells that are 
phase bright following 4 days of differentiation (Fig . 11A). Nearly 40% of all 
OPCs form a dramatically more complex arborization pattern of 04+ OLs (Fig. 
11 B, 12). This coincides with the approximately one-third 01 + population of 
differentiated OPCs with a comparatively complex arborization (Fig. 11 C, 12). 
However, this is accompanied by differentiation of nearly one-third of OPCs to 
GFAP+ astrocytes (Fig. 110, 12). OPCs differentiated into OLs also 
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demonstrated myelin basic protein (MBP) co-immunostaining with 01 + OLs in the 
presence of our standard Differentiation media, though mature OLs were in the 
minority (Fig. 11 E-G). 
Figure 11: OPC differentiation into mature Ols. (A) 4 days following initiation 
of ope differentiation, cells are less phase bright and form more processes, 10X. 
(B-D) Following 7 days of incubation in differentiation media, OLs are highly 
arborized and are 04+ and 01 +. However, there is astrocyte formation as well 
evidenced by GFAP+ cells, 10X. (E-G) 01 + OLs are also MBP+ indicating near 
full maturation and innin of lin 10X. 
OPC/Dorsal root ganglia (DRG) co-culture 
When co-cultured with rat embryonic day 15 DRGs, cortically isolated 
opes consistently aligned with DRG neurites and differentiated into mature OLs 
(Fig. 13). Following 7 days of incubation, co-cultures were A2B5 and NG2 
negative indicating maturation from their precursor phenotype (data not shown). 
Furthermore, opes differentiated into OLs as demonstrated by extensive 04+ 
and 01 + immunostaining of complex and highly arborized OLs (Fig. 13A-F). DRG 
neurite-aligned OLs were also MBP+ suggesting myelin synthesis along DRG 
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axons (Fig. 13G-I). 04, 01, and MBP expression was maintained in co-cultures 
following 14 days of incubation, although there did not appear to be a significant 
difference in staining intensity with any of the three markers compared to co-
cultures following 7 days of incubation (data not shown). 
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Figure 12: ope differentiation 
counts. P1 OPCs differentiated for 
4-6 days resulted in a relatively 
equal distribution of 01 + OLs (32 .39 
+/- 2.08%) and GFAP+ (30.08 +/-
5.04%) astrocytes with a slight 
higher percentage of 04+ OLs 
(39.23 +/- 2.85%). N=2, +/- SD. 
Due to reduced OPC- derived astrocyte differentiation in OPC/DRG co-
cultures, we next differentiated OPCs in the absence of DRGs with conditioned 
media (CM) collected from 7 day incubated co-cultures (Fig . 14). Following 7 
days of incubation , OL maturation comparable to cultures without co-culture CM 
(Fig . 11) was observed as evident in the increased 01 + and MBP+ OLs (Fig. 14B-
D). However, GFAP+ astrocytes were still present as observed with standard 
Differentiation media (Fig . 14A). 
In vitro OPC differentiation leads to a dramatic increase cell death 
(unpublished observations). We previously demonstrated ciliary neurotrophic 
factor (CNTF) improved adult rat spinal cord derived OPC survival both in vitro, 
upon transition to differentiation media, and in vivo following engraftment into the 
injured spinal cord (Cheng et aI. , 2007). Differentiation media supplementation 
with 1 ng/ml CNTF improved survival of mouse OPCs as well (data not shown). 
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Figure 13: OPC maturation into M OLs in OPC/DRG co-culture. P1 OPCs 
co-cultured with rat embryonic DRGs resulted in OPC maturation into highly 
arborized (A-C) 04+ and (D-F) 01 + OLs 7 days following plating. (G-I) Numerous 
OLs formed MBP+ processes around ~-tubulin+ DRG axons. All 
are 10X nification. 
Therefore, 1 ng/ml CNTF was also added to OPCs differentiating co-
culture CM to determine if increased OPC survivability during the early phase of 
OPC maturation will preferentially increase the number of OPCs differentiating 
into OLs (Fig. 14). Following 7 days of incubation, highly complex and mature 
OLs that were 04+, 01 +, and MBP+ had formed (Fig. 14E-H). The degree with 
which mature OLs encompassed large areas of MBP+ immunostaining strongly 
suggests myelin synthesis (Fig. 14G-H). This extent of OPC maturation was not 
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previously seen and can only achieved with CNTF supplementation. However, 
Ols were also accompanied by OPC differentiation into GFAP+ astrocytes 
revealing the continued bi-potentiality of cortically derived postnatal OPC 
differentiation in vitro, with or without CNTF supplementation (Fig. 14E). 
Figure 14: CNTF enhances OPC differentiation in the presence of OPC/DRG 
co-culture CM. (A-D) CM collected from OPC/DRG co-cultures were added to 
differentiating P1 OPCs for 7 days resulting in modest differentiation into 01 + and 
MBP+ Ols. (E-H) However, when this was supplemented with CNTF, a dramatic 
improvement highly mature 01 +/MBP+ Ols formed . This too was accompanied 
by GFAP+ astrocyte differentiation as well. All photomicrographs are 10X 
m nification. 
DISCUSSION 
While numerous reports document the isolation of rat OPCs from 
embryonic, neonatal, and adult CNS, preparations of similarly-derived mouse 
OPCs has proved problematic (Lin et aI., 2006; Chen et aI. , 2007b). Previously 
described mouse OPC culture techniques involve mouse embryonic neurosphere 
formation followed by oligosphere induction for the production of large OPC cell 
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numbers (Chen et aL, 2007b; Zhao et aL, 2010). Immunopanning of postnatal 
mouse brains have previously been described. However, OPCs are positively 
selected on PDGFRaa or A2B5 both of which may yield reduced OPC 
enrichment and the latter may not select exclusively for cells that will differentiate 
within the oligodendrogliallineage (Larsen and Yong, 2004; Cahoy et aL, 2008; 
Dugas et aL, 2010). A2B5+ OPCs have been enriched from postnatal mouse 
brains by magnetic cell sorting (Larsen and Yong, 2004; Hamanoue et aL, 2009). 
However, as the authors acknowledge, single-cell derived clones are selected for 
subsequent plating raising concerns that the cells are in fact immortalized and 
may be genomically unstable, a feature observed with cell lines. To our 
knowledge, this is the first 04+ OPC primary culture method derived from mouse 
postnatal cortex that generates large numbers of OPCs without relying on cell 
immortalization, neurospehere /oligosphere formation, or clonal expansion. 
The genetic, epigenetic, and molecular identity of OPCs derived from in 
vitro "sphere" formation are likely to be considerably different as there induction 
is biologically more distant from there in vivo environment than observed with 
primary cultures (Gage et aL, 1995; D'Amour and Gage, 2003). Furthermore, 
selection of cell clones derived from a single cell following isolation is likely not 
representative of the primary isolated OPC population (Gage et aL, 1995; 
D'Amour and Gage, 2003). The generation of single-cell derived clones 
necessitates that a single OPC will undergo putative proliferative changes in 
order to generate subsequent clones (Lin et aL, 2006). Again, these changes are 
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likely not present in primary cultures, particularly when limited in passage 
number. 
Although this method enriches OPCs based on 04 expression, once 
plated, they are both A2B5+ and NG2+, indicating overlapped expression of all 
three cell markers from cortical OPCs isolates. With PO-P1 expansion, the 
number of 04+ OPCs declines whereas A2B5 and NG2 expression is 
maintained. Despite reduced 04 expression, the OPCs maintain the capacity to 
differentiate into Ols, though the potential to become astrocytes is still present. 
Consistent with reported data for both rat and mouse OPCs, these OPCs 
maintain the capacity to become both astrocytes and Ols (Noble et aL, 1992; 
Nishiyama, 1998; Trotter et aL, 2010). Although CNTF did reduce the extent of 
cell death upon differentiation (as seen with adult rat spinal cord OPCs), the 
number of GFAP+ astrocytes increased (data not shown) (Cheng et aL, 2007; 
Cao et aL, 2010). Though not co-cultured in species matched proliferative 
precursors, OPC/DRG co-cultures resulted in OPC maturation into 01 + positive 
Ols with limited MBP immunoreactivity and minimal GFAP+ astrocyte formation. 
This suggests that soluble factors in these co-cultures, such as the previously 
discussed NRG1, may playa relevant role in promoting preferential OPC 
differentiation into mature Ols rather than astrocytes (Chapter 1). 
OPCs differentiated in the presence of co-culture conditioned media 
supplemented with CNTF resulted in extensive 01 + and MBP+ Ol formation with 
highly complex arborization not seen without the presence of CNTF. This 
suggests CNTF may be playing a synergistic role with soluble factors in the co-
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culture CM to dramatically enhance OPC differentiation. However, a considerable 
number of differentiated astrocytes are observed as well- a role CNTF has been 
previously described to be involved in (Whittemore et aI., 1999). 
Overall, there exists a number of limitations of coritical OPC isolation 
method. As the primary OPCs are passaged beyond P2, they began to 
morphologically resemble type 2 astrocytes. Additionally, one freeze/thaw cycle 
is sufficient to stress these OPCs to differentiate into astrocytes spontaneously. 
Therefore, fresh OPC primary cultures are necessary and it is not recommended 
to take them beyond P2. Despite these issues, this method permits isolation of 
mouse OPCs that obviate potential genomic instability and variability that occur 
with extended passage of other OPC culturing techniques. As a result, we 
contend that these OPCs are as similar as possible to their counterparts in vivo 
and serve as an improved in vitro model for the study of OPCs in development, 
disease, and trauma. 
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CHAPTER 3 
HISTONE DEACETYLASE INHIBITION MEDIATED CYTOTOXICITY OF 
DEVELOPING OLiGODENDROCYTES 
INTRODUCTION 
As previously discussed, post-translational protein deacetylation mediated 
by the 11 member mammalian superfamily of histone deacetylase complexes 
(HDACs) regulates chromatin remodeling, repression of gene transcription, cell 
cycle progression, microtubule dynamics, and cellular aging (Kazantsev and 
Thompson, 2008). Regulation of as histone acetylation status is tightly regulated 
by the activity of both histone acetyltransferases (HATs) and HDACs, of which 
HDACs have received attention due to their variety of function, post-translational 
targets, and the successful development of HDAC specific inhibitors. There are 
many reports of altered HDAC overexpression and activity in various human 
cancers relative to normal tissues (Chapter 1). This prompted the development of 
HDAC inhibitors. A member of the hydroxamic acid class of HDAC inhibitors, 
suberoylanilide hydroxamic acid (SAHA) is the first FDA approved HDAC 
inhibitor. It induces cell growth arrest, apoptosis, DNA damage, reactive oxygen 
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species (ROS) generation, and is anti-angiogenic (Marks, 2007). In a large range 
of human transformed cell lines, HDACi has been implicated in causing cell 
death and SAHA is currently being studied in over 180 clinical trials for the 
treatment of a variety of malignancies, largely in combination with other 
chemotherapeutic agents (www.clinicaltrials.gov).This. in addition to the pan-
HDAC selectivity of many HDAC inhibitors (including SAHA), has spurred the 
development of isoform selective HDACi as well, resulting in more than a dozen 
structurally different HDAC inhibitors currently in clinical trials (Thomas, 2009; 
Bertrand, 2010). 
However, as toxic as HDAC inhibitors are towards transformed cells, there 
too is a growing body of evidence demonstrating its neuroprotective effects in a 
number of neurodegenerative and psychiatric disorders (Chapter 1). However, 
this is further complicated by multiple studies suggesting that HDAC-mediated 
histone deacetylation is necessary for OL differentiation (Chapter 1). These data 
implicate HDACs in a global repressive role in OPC differentiation into mature 
OLs (Shen and Casaccia-Bonnefil, 2008). Ultimately, despite putative 
neuroprotective effects, HDAC inhibition (HDACi) may prevent OPC maturation 
and lead to ineffective myelination in the developing brain. 
Chemotherapy-induced cognitive impairment (CICI) is an accepted and 
common adverse effect of both focal irradiation and systemic chemotherapeutic 
treatment in pediatric and adult patients suffering from hematological and solid 
malignancies (Ahles and Saykin, 2007; Janelsins et aI., 2011). Clinical data show 
incidence of long-term CICI ranging from 16%-75% of cancer survivors with 
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either immediate to delayed onset, with the large variability attributed to cancer 
type, chemotherapeutic agents used, and CICI study methodology (Argyriou et 
aI., 2010). Multiple mechanisms to describe CICI development have been 
suggested such as genetic predisposition, hormonal changes, DNA damage 
secondary to increased oxidative stress, and increased levels of inflammatory 
cytokines (Ahles and Saykin, 2007; Argyriou et aI., 2010). Furthermore, loss of 
CNS progenitors and OLs, and myelinopathy secondary to clinically used 
chemotherapeutic agents in adult mice was demonstrated (Dietrich et aI., 2006). 
However, despite this evidence, CICI pathogenesis remains largely undefined. 
In this study, we investigated the role HDAC activity plays in mouse OPC 
survival and maturation using the blood-brain-barrier (BBB) penetrable HDACi, 
SAHA. As evidenced with many transformed cell lines (Bolden et aI., 2006; Lane 
and Chabner, 2009; Marks, 2010), treatment of normal, non-transformed primary 
OPCs resulted in extensive SAHA mediated toxicity. Furthermore, these in vitro 
results were recapitulated in vivo following SAHA treatment in postnatal day 5 
mouse pups where cortical OPCs in mouse pup brains had greater induction of 
apoptosis than control treated animals. Though demonstrating toxicity towards 
transformed cell lines and even putative neuroprotection in certain models, these 
results demonstrate that SAHA mediated HDACi may be accompanied by the 
death of normal, non-transformed mouse cortical OPCs which may be 
catastrophic to the developing brain and spinal cord. 
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MATERIALS AND METHODS 
Animals 
E12-E15 time pregnant C57BI/6 mice and E15 Sprague-Dawley rats were 
purchased from Charles River Laboratories (Wilmington, MA). CNP-EGFP mice 
backcrossed 6-7 generations to C57BI/6 background were a generous gift from 
Dr. Vittorio Gallo and were bred at the University of Louisville for all in vivo 
experiments (Yuan et aI., 2002). All animal procedures were performed 
according to the guidelines of University of Louisville Institutional Animal Care 
and Use Committee protocols and the National Institutes of Health. 
Mouse Cortical OPC culture 
OPCs derived from postnatal day 5-7 mouse cortices were isolated as 
described previously (Chapter 2). They were expanded to -80% confluence in 7-
9 days with daily feedings of pre-warmed OPC-A media (one day following 
isolation, full media change; every subsequent day until passage, half media 
change). PO OPCs were passaged using Accutase® (Sigma, St. Louis, MO) 
according to the manufacturer's protocol and plated in poly-D-Iysine 
(PDL)/Iaminin coated tissue coated dishes appropriate for subsequent 
experiments at a seeding density of 10,000-15,000 OPCs/cm2. Where 
appropriate, following five days of expansion in OPC-A media, P1 OPCs were 
permitted to differentiate into mature OLs for seven days with removal of PDGF-
AA and FGF-2 and the addition of T3 at 40 ng/ml or astrocytes in DMEM-F12 
media (50% v/v) containing 10% BSA. 
RNA Extraction and reverse transcriptase PCR 
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OPCs, enriched astrocytes, and OLs were lysed in TRIZOL ® Reagent 
(Invitrogen, Carlsbad, CA) and extracted according to the manufacturer's 
protocol. RNA was further purified using the Qiagen MinElute Kit (Qiagen, 
Valencia, CA) and concentrations were confirmed by UV spectroscopy. Following 
total RNA isolation, 250 ng of total RNA was used for first strand cDNA synthesis 
according to the manufacturer's protocol using the RT2 PCR First Strand 
Synthesis Kit (SABiosciences Corp., Frederick, MD). As controls, samples 
containing all components except reverse transcriptase or no sample were 
treated similarly. 
qRT -peR Analyses 
qRT-PCR was performed using ABI 7900HT Real-time PCR instrument 
(Applied Biosystems, Foster City, CA). Briefly, cDNAs were added to pre-
designed RT2 qPCR Primer Assays (SABiosciences Corp.) for each HDAC 
isoform and mixed with SYBR Green/Rox Master Mix in separate reaction 
mixtures for all reactions and run in triplicate. The RNA levels were quantified 
using the ddCT method. Expression values obtained from triplicate runs of each 
cDNA sample were normalized to triplicate value for GAPDH (reference gene) 
from the same cDNA preparation. 
SAHA Treatment and MIT Analysis 
P1 OPCs were plated into 96-well plates and allowed to expand for five 
days prior to treatment. OPC survival was assayed by measuring the conversion 
of the yellow, water-soluble tetrazolium, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) to the blue, water-insoluble formazan. This 
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conversion is catalyzed by cellular mitochondrial dehydrogenases. As the rate of 
this reaction is proportional to the number of surviving cells, the MTT assay is 
widely used to quantify viable cells (Ohri et aI., 2011). Data are presented as the 
percentage of survival relative to vehicle-treated controls. SAHA (Cayman 
Chemical, Ann Arbor, MI) stock was prepared in DMSO (75 mM) and diluted in 
appropriate media (OPC-A, astrocyte differentiation, or OL differentiation) to final 
treatment concentrations of 250 nM, 500 nM, 1 I-IM, and 2.5 I-IM. Vehicle-treated 
controls had DMSO concentration equivalent to the highest SAHA concentration 
used (0.0033%). 
Total Protein and Histone Extraction for Western Analyses 
OPCs, OPC-derived enriched astrocytes, or OPC-derived OLs were 
washed once in DPBS and then lysed in SDS-PAGE sample buffer for cleaved 
caspase 3 and l3-actin isolation. Histones were purified from cells or cortical 
tissue using the Epiquik® Total Histone Extraction Kit (Epigentek, Farmingdale, 
NY) according to the manufacturer's protocol. Following transfer onto 
nitrocellulose membranes, Western blots were blocked in 5% milk in TBS with 
0.1 % Tween (TBST) for one hour at room temperature. Primary antibodies were 
incubated overnight in 4°C TBST with 5% BSA followed by secondary antibodies 
in TBST with 5% BSA for one hour at room temperature. Following film 
development, blots were digitized and quantified using the ImageQuant TL 
v2003.02 software. Primary antibodies used were rabbit-anti cleaved caspase 3 
(1:1000 Cell Signaling, Beverly, MA), mouse-anti l3-actin (1 :2000), rabbit anti-
acetylated histone H3 (1:1000, Millipore, Billerica, MA), rabbit anti-acetylated 
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histone H4 (1:1000, Abd Serotec, Raleigh, NC), mouse anti-total histone H3 
(1:1000, Millipore), and mouse anti-total histone H4 (1:1000, Cell Signaling). 
Secondary antibodies used were horseradish peroxidase (HRP) anti-rabbit and 
HRP anti-mouse (1 :10,000). 
In Vivo SAHA Cytotoxicity and Immunohistochemistry 
Postnatal day 5 CNP-EGFP mouse pups weighing approximately 3g were 
treated with SAHA (50 mg/kg s.c.) or vehicle (75%/25% v/v OMSO/normal saline, 
s.c.) twice daily for 2.5 days. Following anesthetizing on ice, pups were 
transcardially perfused initially with PBS followed by 4% paraformaldehyde. 
Brains were then dissected and post-fixed for 48 hours followed by 30% sucrose 
immersion. Afterwards, brains were placed in TBS freezing media overnight and 
sectioned into 20 IJm slices using a cryostat and placed on slides. 
For immunohistochemistry, sections were thawed and washed in PBS for 
10 min. Then sections were blocked in 10% normal donkey serum (NOS) and 1 % 
BSA in PBS/O.3% Triton (PBST) for 1 hour at room temperature. Sections were 
then washed in PBS for 10 min. and incubated overnight in 5% NOS, 0.5% BSA, 
and primary antibodies in PBST. The next day, sections were washed 4 x 15 min. 
in PBS and incubated in 5% NOS, 0.5% BSA, and secondary antibodies in PBST 
for 1 hour at room temperature. Sections were washed 4 x 15 min. in PBS 
mounted and cover-slipped using Flouromount G mounting media (Southern 
Biotech, Birgmingham, AL). Primary antibodies used included rabbit anti-cleaved 
caspase 3 (1 :200, Cell Signaling) to visualize cells undergoing caspase-
dependent apoptosis and Hoechst to stain cellular nuclei. Secondary antibodies 
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used were donkey anti- rabbit TRITC and donkey anti- mouse TRITC (1 :200, 
Jackson ImmunoResearch, West Grove, PA). Sections were captured with a 
Nikon TiE 300 inverted microscope equipped with a DXM-1200C coded digital 
camera and NIS Elements software (Nikon, Melville, NY). 
To assess in vivo SAHA cytotoxicity, absolute cell counts staining positive 
for cleaved caspase 3 and/or CNPase-EGFP were completed from 3 randomly 
selected sections for each animal encompassing a region of the brain that 
correspond to Intraaural 1.68mm to 2.16mm and Bregma -2.12mm to -1.64mm in 
the adult C57BLl6 brain. These were quantified by an individual blinded to animal 
treatments. Counts were only from cells lying within the cortex. Brain regions 
such as basal ganglia, brain stem, hippocampus, etc. were excluded from the 
analysis. 
Statistical Analysis 
All quantitative data are presented as means +/- S.D. qRT-PCR data 
analyses were completed as described above and according to the 
manufacturer's recommended statistical analysis methods. Statistical 
significance for MTT analyses as determined by conducting a One-Way ANOVA 
for each SAHA treatment group relative to the DMSO vehicle treated groups. 
Counts were averaged for each animal and an F-test to determine sample 
variance was completed to assess equal variance between the two treatment 
groups. Afterwards, statistical significance was determined using an independent 
t-test assuming equal variances. In vivo CNPase+ and/or cleaved caspase 3+ cell 
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counts were analyzed by an F-test to determine sample variance after which an 
independent t-test assuming equal variances was conducted. 
RESULTS 
HDAC expression characterization in mouse OPC cultures 
We characterized HDAC expression in mouse OPCs as well as OPC-
derived astrocytes and mature OLs and determined if any expression changes 
corresponded to change in proliferative state and differentiated cell type (Fig. 15). 
OPCs, as well as OPC-derived OLs and astrocytes expressed all HDAC isoforms 
(Fig. 15). More specifically, OLs showed a significant decrease in the class I 
HDAC2 isoform and II HDACs 4, 5, and 6 relative to proliferative OPCs 
maintained in growth media (Fig. 15A-C). Class I HDACs 1, 2, and 3 significantly 
decrease in expression during OPC differentiation into astrocytes relative to 
OPCs (Fig. 15A). Expression of Class lIa HDAC isoforms in astrocytes relative to 
OPCs remain largely unchanged (Fig. 158). Class lib HDAC isoform HDAC10 
also significantly decreases in expression in OPC-derived astrocytes relative 
Undifferentiating OPCs (Fig 15C). Overall, including a variety of changes in 
HDAC expression that is largely decreased in OLs and astrocytes derived from 
OPCs relative to the undifferentiated OPCs in proliferative cell culture media, 
these data suggest that all HDAC isoforms have expression patterns that are 
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Figure 15: HDAC expression in 
mouse OLs and astrocytes relative 
to OPCs. (A-C) All HDAC isoforms are 
expressed in cortically isolated OPCs 
just prior to in vitro induction of 
differentiation. Astrocytes and Ols 
derived from OPCs also ubiquitously 
express all HDAC members. As a 
whole, HDAC expression is reduced 7 
days following OPC differentiation into 
astrocytes and Ols. (A) HDACs 1, 2, 
and 3 decrease in expression in 
astrocytes whereas only HDAC2 does 
in Ols. (B) HDACs 4, 5, and 7 
decrease in expression in Ols relative 
to OPCs. (C) HDAC 6 decreases in 
expression in Ol relative to OPCs and 
HDAC 10 significantly decreases in 
expression during astrocyte 
differentiation relative to OPCs. All 
data presented are average fold 
change of HDAC expression in Ols 
and astrocytes relative to OPCs . 
GAPDH housekeeper. * p < 0.05 
SAHA mediated cytotoxicity in mouse OPCs 
To assess SAHA mediated pan-HDAC inhibition, we treated P1 OPCs in 
vitro in escalating doses of 250 nM, 500 nM, 1 ~M , and 2.5 ~M for 24, 48, and 72 
hours (Fig. 16). These SAHA concentrations were selected based on previous 
studies indicating both survivability in CNS cell cultures, but also toxicity in 
transformed cells lines- although SAHA concentrations below 1 ~M were rarely 
tested (Bolden et aI., 2006; Bertrand, 2010; Marks, 2010). Three hours following 
SAHA treatment, OPCs at all concentrations showed increased levels of 
acetylated histone H3 and a dose-dependent increase in acetylated histone H4 
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Figure 16: HDACi-mediated cytotoxicity of OPCs. (A) 3 hrs. following SAHA 
administration, drug activity is confirmed by an increase in acetylated histone H3 
and a dose-dependent increase in acetylated histone H4. (8) MTT analysis of 
SAHA treated opes resulted in significant decreases in cell survival 48 and 72 
hrs following treatment. In increasing dose of SAHA concentration , there was 
90.95%, 88.74%, 69.00%, and 54.8% ope survival relative to vehicle treated 
controls following 48 hrs. of SAHA treatment. There was 90.40%, 79.28%, 
49.17%, and 32.43% ope survival relative to vehicle controls following 72 hrs. of 
SAHA treatment. N = 3 for each SAHA concentration tested . (e) Representative 
phase contrast images of opes following 72 hrs. of SAHA treatment. Decreased 
ope survival is clearly evident, particularly at the higher SAHA concentrations. * 
p < 0.05 following 48 and 72 hrs. of SAHA treatment for all concentrations 
relative to vehicle treated controls. 
To determine the effect on ope survival , MTT analysis revealed extensive 
cell death following SAHA treatment for 48-72 hours. The greatest cell death was 
observed at 48 and 72 hours of SAHA treatment where approximately 50% and 
35% of 2.5 !-1M treated opes survived relative to vehicle treated opes, 
respectively (Fig . 168). Significant cell death was also seen at 1 !-1M SAHA 
treatment where approximately half all opes survived relative to vehicle treated 
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OPCs (Fig. 168). Though significant, considerably less cell death was observed 
following 72 hours of 250 nM and 500 nM SAHA treatment of OPCs relative to 
vehicle controls (Fig. 168). Representative images of OPCs following SAHA 
administration clearly illustrate the cytotoxic effect HDACi has on OPC survival at 
all SAHA concentrations relative to vehicle treated OPCs (Fig. 16C). The 
remaining cells were A285+, 04+, 01 -, and GFAP- (unpublished observations). 
To determine if differentiated OPCs have similar susceptibility to SAHA 
mediated cytotoxicity, OPCs were differentiated for 7 days either into astrocytes 
(removal of growth factors accompanied by 10% serum) or to an enriched 
population of complexly arborized 04+ and/or 01 + Ols. As with OPCs, the 
greatest cell death was seen at 72 hours of 2.5 IJM SAHA treatment (Fig . 17). 
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Figure 17: OPC derived OL and 
astrocyte survival following HDACi. 
(A) MTT analysis revealed SAHA 
treatment of OPC derived Ols only 
significantly causes increased cell 
death following 72 hrs. of treatment at 
1 IJM and 2.5 IJM of SAHA with an 
average of 79.07% and 66.91 % cell 
survival relative to vehicle treated 
controls, respectively. (8) Significant 
yet modest cell death was observed in 
OPC derived astrocytes 48 and 72 
hours following SAHA administration. 
This was seen at 1 IJM and 2.5 IJM of 
SAHA as well with 91 .93% and 84.64% 
survival at 48 hrs. and 84.64% and 
73.10% survival at 72 hrs., 
respectively. * p < 0.05 only at 1 IJM 
and 2.5 IJM. N = 3 for each 
concentration. 
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However, these were considerably less than observed in OPCs. OPCs following 
7 days of differentiation in OL differentiation media and treated with 2.5 !-1M 
SAHA for 72 hours experienced approximately a 25% loss of cell survival relative 
to vehicle treated controls (Fig. 17 A). OPC-derived astrocytes saw a similar loss 
in cell survivability (Fig. 178). Though cell death was statistically significant, it 
appears to be considerably more protracted and far less toxic in mature glial cells 
relative to their progenitors. 
Caspase activation following SAHA treatment in OPCs 
SAHA-mediated activation of apoptotic caspase-dependant and 
independent pathways in response to reactive oxygen species generation and 
subsequent DNA double strand breaks have been implicated in selective cell 
death of numerous cancer cell lines (Lee et aI., 2010; Marks, 2010). As 
differentiated OPCs displayed a reduced susceptibility to SAHA mediated cell 
death relative to OPCs, we wanted to investigate whether this death was a 
caspase-dependant apoptosis. Cleaved caspase 3 (CC3) is present as early as 
24 hours of SAHA treatment across all four SAHA concentrations (Fig. 18A). This 
indicates that, at least in part, SAHA-mediated OPC death is a caspase-
dependent apoptotic process (Fig. 18A). We hypothesized that the greatest 
caspase activation likely occurs following 1 !-1M and 2.5 !-1M SAHA treatment. 
Therefore, OPCs were treated with SAHA and the potent general caspase 
inhibitor Q-VD-OPH following SAHA administration for 48 and 72 hours. Q-VD-
OPH administration before or at the time of SAHA administration did not improve 
cell survival and therefore it was determined Q-VD-OPH administration just prior 
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to caspase activation (16-18 hrs. following SAHA administration) is necessary 
and would maximize the caspase inhibitory effect (data not shown). Phase 
contrast images of OPCs that received Q-VO-OPH following 2.5 IJM SAHA 
addition displayed increased cell survival (Fig. 188). 10 IJM Q-VO-OPH treatment 
following 1 IJM and 2.5 IJM SAHA treatment resulted in nearly 50% increased cell 
survival relative to SAHA only treated OPCs (Fig. 18C). However, cell survival 
did not return to normal suggesting caspase-independent cell death pathways 
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Figure 18: SAHA-mediated HDACi partially results in caspase mediated 
apoptosis. (A) Cleaved caspase 3 indicating caspase activation is seen 24 hrs. 
at all concentrations following SAHA administration to OPCs. (8) Representative 
images showing increased OPC survival when the general caspase inhibitor 10 
IJM Q-VO-OPH is added 16-18 hrs. following SAHA administration. (C) 10 IJM Q-
VO-OPH significantly improved OPC survival in 72 hr. 1 IJM SAHA treated OPCs; 
59.68% vs. 33.85% OPC survival relative to vehicle treated OPCs. (0) 10 IJM Q-
VO-OPH significantly improved OPC survival in OPCs treated with 48 and 72 hrs. 
2.5 IJM SAHA treatment. 48hr.: 59.63% vs. 38.13%, 72hrs.: 47.19% vs. 24.38% 
OPC survival relative to vehicle treated OPCs. * p < 0.05 for Q-VO-OPH/SAHA 
treated OPCs compared to SAHA alone. N = 3 for all treatments. 
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SAHA is cytotoxic to cortical opes in vivo 
To determine whether this effect is evident in vivo as well, P5 CNPase-
EGFP pups were administered either SAHA (50 mg/kg, twice daily, s.c.) or 
vehicle for 2.5 days (total of 5 infusions). Though often used as a marker of 
oligodendroglial maturity, CNPase expression early in the oligodendroglial 
lineage (Yuan et aI., 2002; Lytle et aI., 2009). Furthermore, mouse pup brains 
and spinal cords begin actively myelintating between postnatal days 7-21 (Miller 
and Mi, 2007; Nishiyama et aI., 2009). These pups were treated prior to onset of 
active myelination, and thus had a reduced number of mature myelinating OLs 
relative to adults as OPCs are only beginning to mature into OLs at this 
developmental time point (Wolswijk and Noble, 1989; Noble et aI., 1992; Miller 
and Mi, 2007; Nishiyama et aI., 2009). Therefore, CNPase-EGFP+ cells in the 
brain at this age range serve as a reliable marker for OPCs in vivo. 
Representative brain hemisections from mouse pup brains demonstrate 
the approximate regions examined for subsequent quantitative analysis (Fig. 19). 
Though not further investigated, brains from SAHA treated mice did appear to 
have reduced CNPase-EGFP expression relative to brains of vehicle treated 
pups (data not shown). Vehicle-treated mouse pups had multiple brain regions 
nearly without any cells that were CC3+, particularly CC3+/CNPase-EGFP+ OPCs 
(Fig. 20A-C). This was in stark contrast to SAHA-treated mouse pups as they 
had multiple brain regions, such as the lateral cortex and regions not used for 
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quantification including many areas in the diencephalon, with CC3+ /CNPase-
EGFP+ OPCs demonstrating induction of OPC apoptosis (Fig. 200-1). 
As our OPC cultures are derived originally from mouse cortices, we only 
quantified the number of CC3+ and CC3/CNPase + cells from the cortex, 
excluding cell counts from the structures such as the brain stem, cerebellum, 
olfactory bulb, and hippocampus (Fig. 21A). SAHA treated animals had 
significantly greater CC3 positive cells in their cortices compared to vehicle 
treated mice (Fig. 218). Additionally, SAHA treated mice had a significantly 
greater number of cortical CC3+/CNPase+ OPCs relative to vehicle treated 
animals indicating greater SAHA mediated cytotoxicity of cortical OPCs in vivo 
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Figure 20: Co-localization of cleaved caspase 3 with CNPase OPCs 
following SAHA treatment in vivo. Representative image from lateral cortex 
(A-C) Vehicle treated P7 mouse pup showing lack of CC3 immunostaining of 
CNPase-EGFP+ OPCs and (D-F) SAHA treated P7 mouse pups showing multiple 
CC3+ immunostained cells that are also CNPase-EGFP+ oPCs. (G-I) Inset of 
images D-F demonstrating clear CC3 immuno-staining of CNPase-EGFP+ oPCs. 
10X hotomi G-I 40X otom' 
(Fig. 21 C). Of interesting note, a majority of CC3+ and CC3/CNPase + cells are 
located in the lateral cortices of the developing mouse pup brain (data not 
shown). This may either be a byproduct of increased blood flow to those cortical 
regions resulting in increased SAHA exposure to effected cells or subpopulations 
of cells that are preferentially susceptible to HDACi-mediated cytotoxicity. 
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Figure 21: HDACi results in 
increased cortical OPC 
cytotoxicity in vivo. (A) Brain 
hemisections illustrating region 
excluded from cell counts. Cortical 
region surrounding the red line was 
the only area included in counts. 
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(B) There is a significant increase in the number of CC3 cells/section analyzed 
relative to vehicle treated controls. A mean of 218.00 +/- 18.46 cells were CC3+ 
in SAHA treated brains compared to a mean of 88.11 +/- 22.94 in vehicle treated 
animals. (C) There also is a significant increase in the number of CC3+/CNPase-
EGFP+ cells/section analyzed relative to vehicle treated controls. A mean of 
84.33 +/- 16.50 cells were CC3+ in SAHA treated brains compared to a mean of 
34.00 +/- 10.90 in vehicle treated animals. ** p < 0.01 , * P < 0.05. N = 3 for each 
SAHA may be cytotoxic to neurons of the developing mouse brain 
Though not quantified, there is clear evidence of specific neuronal toxicity 
in the superficial cortex of the mouse developing cortex in SAHA treated animals 
compared to vehicle treated pups (Fig . 22). SAHA treated animals have a 
population of CC3+ /NeuN+ neurons located in superficial cortical gray matter that 
is absent in vehicle treated mice (Fig . 22A-D). This cell death may also account 
for the increased number of CC3+/CNPase- cells that morphologically resemble 
neurons in SAHA treated pups suggesting the additional possibility of neuronal 
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toxicity in the developing mouse brain as well as its effects on developing OLs 
(Fig. 21-22). 
Figure 22: Putative neuronal toxicity in the superficial cortex following in 
vivo SAHA administration. (A) Observation of CC3+ cells located in the medial 
superficial cortex only in SAHA treated P7 mouse pups that are not (B-C) 
CNPase-EGFP+ OPCs. Rather they morphologically resemble neurons and are 
and are located in a (D) cell dense region typical of cortical gray matter. Scale 
bar = 50 m. 
DISCUSSION 
HDAC inhibition mediated by valproic acid and trichostatin A (TSA) 
promotes cell cycle arrest and increases expression of OPC maturation 
inhibitors, thereby preventing mature oligodendrocyte formation (Shen and 
Casaccia-Bonnefil , 2008; Shen et aI. , 2008; Pedre et aI. , 2011). Additionally, 
previous reports have indicated cytotoxicity of renal tubular cells and immature 
osteoblasts but studies on the developing central nervous system were lacking 
(Dong et aI. , 2008; McGee-Lawrence et aI. , 2011). There has been increased 
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development of new HDAC inhibitors by the scientific community, putative 
successes of HDAC inhibitors as chemotherapeutic agents and multiple studies 
suggesting HDACi-mediated neuroprotective effects in vitro and in vivo (Abel and 
Zukin, 2008). We wanted to determine what effect transient inhibition of HDAC 
activity would have on OPC survival. Based on these previous data we 
hypothesized that SAHA-mediated HDACi may result in improved OPC cell 
survival in the presence of an exogenous stressor, however, we demonstrate 
transient SAHA-mediated HDACi leads to dramatic OPC cytotoxicity both in vitro 
and in vivo. 
We selected a SAHA dose range that was previously shown to either be 
effective in reducing cell viability of transformed cells lines and/or beneficial in a 
neurological disease model in vitro (Bertrand, 2010; Colussi et aI., 2010; Kidd 
and Schneider, 2010; Lee et aI., 2010; Chen et aI., 2011). Surprisingly, at a 
concentration as low as 0.5 IJM SAHA demonstrates cell death up to 72 hours of 
treatment. It was not necessary to attempt concentrations greater than 2.5 IJM as 
a large extent of the cell population had already been killed. 
As OPCs are proliferative, it became necessary to determine if this 
cytotoxicity extended to their terminally differentiated phenotypes. The 
bipotentiality of this cell population made it necessary to investigate whether this 
toxicity extended to OPC-derived astrocytes and OPC-derived OLs separately 
(Fig. 17). Though a 20-30% cell death following SAHA treatment for 72 hours is 
observed, this effect is likely due to undifferentiated OPCs that maintained some 
proliferative capacity that were still susceptible to SAHA mediated cytotoxicity. 
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Though astrocyte and OL death was significant at the higher SAHA 
concentrations relative to their vehicle treated counterparts, we sought to further 
determine the cause of the more robust death observed at multiple 
concentrations in OPCs. 
Caspase activation was evident as early as 24 hours following SAHA 
administration and increased dramatically up to 48 hours following treatment as 
determined by Western analysis (data not shown). We only observed a partial 
increase in cell survival at the two highest tested SAHA concentrations following 
treatment with the general caspase inhibitor Q-VD-OPH (Fig. 18). Therefore, 
caspase independent pathways are also likely involved in SAHA mediated 
induction of apoptosis such as caspase-independent release of apoptosis-
inducing factor (AIF) which has been previously correlated to SAHA-mediated 
potentiation of transformed human leukemia and multiple myeloma cell lines 
when combined with doxorubicin (Cheriyath et aI., 2011). Similar to other HDAC 
inhibitors, SAHA can induce both G1 and G2/M cell cycle arrest (Marin-Husstege 
et aI., 2002; Bolden et aI., 2006). Additional differences between MTI values 
may be representative of vehicle treated cells maintaining their proliferative 
capacity relative to SAHA treated OPCs over 72 hours of treatment. As our study 
examined SAHA mediated cell death, we did not direct our investigation on its 
effect on induction of cell cycle arrest. 
As clinical trials have been initiated for administration of SAHA to pediatric 
patient populations suffering from a variety of hematological cancers and solid 
tumors, potential oligodendrotoxicity in mammalian models have yet to be 
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assessed. In light of this, we were surprised to see the more than 2-fold increase 
in OPC death in vivo following transient SAHA administration. As SAHA 
treatment is typically proposed to extend over a course of 1-2 months, the 
increased cell death following only 48 hours of treatment needs to be 
emphasized. It is important to note that although we used CC3 as our marker for 
in vivo cell death, this does not include OPCs that have already died, undergone 
caspase-independent apoptosis, or experienced extensive injury/stress but have 
not yet initiated caspase-dependent apoptosis. Therefore, the potential in vivo 
cytotoxicity is likely even greater than that measured in our study. 
Though still limited in scope, a well-defined cellular and molecular basis 
remains elusive in CICI in adults and children. A large majority of the data CICI in 
adults comes from breast cancer survivors where decline in cognitive function is 
evident years following treatment. However, it still remains unclear if this decline 
is reversible. Cranial radiation is shown to reduce hippocampal neurogenesis in 
both rodent models and children undergoing focal radiotherapy for CNS tumors 
(Monje, 2008). Furthermore, intrathecal methotrexate for the treatment of 
medulloblastoma resulted in increased cognitive deficits in children (Butler et aI., 
1994). Therefore, chemotherapeutic agent induced CNS toxicity is dependent on 
the agent in question, its route of administration, ability to penetrate the blood-
brain-barrier if given peripherally, the length of treatment, and the patient's age. 
We did not determine the mechanism by which SAHA-mediated HDACi 
causes direct OPC toxicity. It was recently demonstrated that SAHA exposure in 
vitro resulted in increased DNA double-strand breaks (DSBs) secondary to 
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increased reactive oxygen species (ROS) generation. Furthermore, they 
indicated that specific transformed cell cytotoxicity by SAHA is due to their 
reduced capacity for DNA DSB repair compared to normal, non-transformed cells 
(Lee et aI., 2010). However, this study used fibroblasts and, with the present 
evidence in mind, may call for a need to assess chemotherapeutic agent 
mediated toxicities on other more susceptible CNS cellular populations, such as 
cells of the OL lineage. 
Often in assessing CICI, a majority of work emphasizes effects on 
neurotoxicity or reduction of neurogenesis. Unfortunately, work on 
oligodendrotoxicity following treatment with chemotherapeutic agents is limited. 
Carmustine, cisplatin, and cytosine arabinoside, have been demonstrated to be 
toxic to CNS progenitors as well as OLs (Dietrich et aI., 2006). Furthermore, 5-
fluorouracil administration in adult rats result in delayed myelin destruction in 
CNS tracts (Han et aI., 2008). Ultimately, additional work is necessary to 
determine if cognitive decline observed in CICI is, at least in part, secondary to 
reduced OPC and/or OL survival, leading to reduced or delayed CNS 
myelination. 
Although recent evidence suggests a putative protective role for HDAC 
inhibition on white matter sparing, the body of evidence implicates HDACi to be 
detrimental to by induction of OPC cell cycle arrest and prevention of OPC 
maturation (Shen and Casaccia-Bonnefil, 2008; Dietz and Casaccia, 2010). Our 
work adds to this by demonstrating that pan-HDAC inhibition, as mediated by the 
FDA approved small molecule HDAC inhibitor SAHA, induces OPC apoptosis in 
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vitro and in vivo. With current use of this drug in cancer treatment, continued 
development of HDACi's, discussion of small molecule HDACi use in the 
treatment of neuropsychiatric illnesses, and over 180 clinical trials using SAHA, it 
is necessary to reassess the clinical use and CNS toxicity associated with 




SPINAL CORD-DERIVED RAT OLIGODENDROCYTE SUSUCEPTIBILITY TO 
HISTONE DEACETYLASE INHIBITION 
INTRODUCTION 
Myelination of the central nervous system (CNS) is mediated by mature 
oligodendrocytes (OLs). During mammalian development oligodendrocyte 
precursor cells (OPCs) differentiate into OLs with subsequent CNS myelination 
occurring in rodents 1-3 weeks postnatally (Knobler et aI., 1974; Wolswijk and 
Noble, 1989; Noble et aI., 1992; Nishiyama, 1998). OPCs are also present in the 
adult mammalian CNS and may be involved in myelin turnover and remyelination 
in normal or diseased/injured CNS states, respectively (Thuret et aI., 2006; 
McTigue and Tripathi, 2008). Therefore, it is important to identify mechanisms 
that govern OPC and OL survival and death to better understand putative 
disease processes that involve oligodendrocyte pathology such as multiple 
sclerosis, traumatic CNS injury, and leukodystrophies. 
Post-translational protein deacetylation mediated by the 11 member 
mammalian superfamily of histone deacetylase complexes (HDACs) regulates 
chromatin remodeling, repression of gene transcription, cell cycle progression, 
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microtubule dynamics, and cellular aging (Kazantsev and Thompson, 2008). 
Several studies indicate that HDAC-mediated histone deacetylation is necessary 
for Ol differentiation (Marin-Husstege et aI., 2002; Shen et aI., 2008). Valproic 
acid (VPA)-mediated HDAC inhibition (HDACi) in neonatal rats resulted in 
hypomyelination of the corpus callosum due to reduction of OPC differentiation 
into Ols (Shen et aI., 2005). Furthermore, HDAC1/2-mediated disruption of the 
Wnt signaling pathway is necessary for Ol maturation (Li and Richardson, 2009; 
Ye et aI., 2009). VPA treatment in cuprizone-exposed mice prevented 
remyelination of the corpus callosum due to reduced OPC differentiation (Shen et 
aI., 2008). Recently, studies showing increased histone acetylation in chronic 
multiple sclerosis lesions in the frontal lobe white matter suggest reduced 
efficiency of HDAC activity which may be responsible for reduced remyelinating 
efficiency (Shen et aI., 2008; Pedre et aI., 2011). 
Despite these findings, HDAC inhibitors continue to be developed and 
tested in numerous clinical trials in combinatorial therapies with DNA damaging 
chemotherapeutic agents as there is a large body of evidence implicating their 
efficacy as anti-cancer agents (Marks, 2010). Additionally, the previously 
described effects of HDAC inhibition on Ol differentiation were largely on class I 
HDAC isoforms rather than the FDA approved and clinically used pan-HDAC 
inhibitor suberoylanilide hydroxamic acid (SAHA). 
This has immediate implication in the understanding of chemotherapy 
induced cognitive impairment (CICI). loss of CNS progenitors, Ols, and 
myelinopathy in adult mice secondary to chemotherapeutic agents as previously 
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discussed and extensively reviewed (Chapter 1). However, as a whole, CICI 
pathogenesis remains largely undefined. Therefore, we investigated whether 
SAHA mediated susceptibility is evident in rat OPCs and putative mechanisms 
that may be involved. Present data show both rat OPC and OL susceptibility to 
pan-HDACi which suggest that current clinical treatment paradigms that involve 
pan-HDACi may prove as toxic to the myelinating or remyelinating CNS- as they 
are to transformed cells, their intended target. 
MATERIAL AND METHODS 
Rat Adult Spinal Cord OPC culture 
Rat OPCs were isolated as previously described (Talbott et aI., 2006; 
Cheng et aI., 2007). Briefly, dissected spinal cords from adult Fischer 344 rats 
were minced into 1 mm3 pieces and incubated in HBSS (Invitrogen, Carlsbad, 
CA) containing 0.1 % papain, 0.1 % neutral protease, and 0.01 % DNase (all from 
Worthington Biochemical, Lakewood, NJ) for 30 min at 37°C. Tissue digestion 
was stopped with the addition of an equal volume of DMEM containing 20% fetal 
bovine serum (FBS, Invitrogen). Tissue was further dissociated by repeated 
trituration with fire-polished Pasteur pipettes and filtered through 70 IJm nylon 
mesh. Cells were first incubated on an anti-RAN-2 antibody-coated dish for 30 
min to deplete type 1 astrocytes and meningeal cells then transferred to an 04-
coated dish for 45 min to select OPCs. Purified OPCs on the dish were removed 
with trypsin (Invitrogen) and cultured in poly-d-Iysine/laminin-coated dishes with 
DMEM/F12 medium containing Penicillin/Streptomycin (1 %), N2 (1 %) and B27 
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(2%) supplements (all from Invitrogen), fibroblast growth factor 2 (FGF2) (20 
ng/ml; Millipore, Billerica, MA), platelet-derived growth factor aa (POGFaa) (10 
ng/ml; Sigma, St. Louis, MO), insulin (5 IJg/ml), and BSA (0.1 %). Cells were fed 
with half-fresh growth medium every other day. In all cases, an aliquot of cells 
was analyzed the next day to determine the efficiency of the immunopanning and 
only cell preparations with >95% of the bound cells expressed 04 were used. 
ope Immunocytochemistry 
Immunocytochemical analysis of OPC cultures were done as previously 
described (Talbott et aI., 2006; Cheng et aI., 2007). Briefly, cells were washed in 
OPBS and then incubated with hybridoma for 45 minutes at 4°C. Afterwards cells 
were fixed in 4% paraformaldehyde at room temperature for 10 minutes. Cells 
were blocked and incubated overnight with antibody in 4°C with 10% normal 
donkey serum (NOS, Jackson ImmunoResearch, West Grove, PA), 0.5% BSA 
(Sigma), and 0.1 % Triton X-1 00 in OPBS. The following day, cells were 
incubated in secondary antibody at room temperature for one hour in 5% NOS, 
0.5% BSA, and 0.1 % triton in OPBS. Antibodies used include mouse anti-A2B5 
IgM, mouse anti-04 IgM, and mouse anti-01 IgM (a gift from Patrick Wood, 
University of Miami, 70% v/v in OPBS), rabbit anti-NG2 (1 :500, Millipore), rat anti-
MBP (1 :100, Millipore), and rabbit anti-GFAP (1 :500, Oako, Glostrup, Denmark). 
Cells were incubated with FITC, Texas Red, and Rhodamine Red conjugated 
F(ab'h fragment antibodies (Jackson Immunoresearch). Negative controls fo'r 
antibody staining included the appropriate species-specific non-immune IgG or 
IgM antibodies. 10X and 20X photomicrographs were captured with a Nikon TiE 
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300 inverted microscope equipped with a DXM-1200C coded digital camera and 
NIS Elements software (Nikon, Melville, NY). 63X photomicrographs were 
captured with the Zeiss AxioObserver inverted microscopes with AxioVision 
software (Carl Zeiss Microlmaging, Thornwood, NY). 
Drug Treatments and MTT Analysis 
P1 OPCs were plated into 96-well plates and allowed to expand for five 
days prior to treatment. OPC survival was assayed by measuring the conversion 
of the yellow, water-soluble tetrazolium, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; Sigma) to the blue, water-insoluble formazan. This 
conversion is catalyzed by cellular mitochondrial dehydrogenases. As the rate of 
this reaction is proportional to the number of surviving cells, the MTT assay is 
widely used to quantify viable cells (Ohri et aI., 2011). Data are presented as the 
percentage of survival relative to vehicle-treated controls. SAHA (75 mM in 
DMSO; Cayman Chemical, Ann Arbor, MI), Q-VD-OPH (20 mM in DMSO; R&D 
Systems, Minneapolis, MN), and Pifithrin-a (50 mM in DMSO; EMD Chemicals, 
Rockland, MA) stocks were prepared and diluted in appropriate media (OPC or 
differentiation) to final treatment concentrations. 
Protein Extraction and Western Analyses 
Cells were washed once in DPBS and then lysed either in SDS-PAGE 
sample buffer or NTEN buffer for separate nuclear Iysates. Following transfer 
onto nitrocellulose membranes, Western blots were blocked in 5% milk in TBS 
with 0.1 % Tween-20 (TBST) for one hour at room temperature. Primary 
antibodies were incubated overnight in 4°C TBST with 5% BSA followed by3 
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washes for 10 minutes in TBST, then addition of secondary antibodies in TBST 
with 5% BSA for one hour at room temperature. Primary antibodies used were 
rabbit anti-cleaved caspase 3 (1:1000 Cell Signaling, Beverly, MA), mouse-anti 
~-actin (1 :2000), rabbit anti-acetylated histone H3 (1 :1000, Millipore, Billerica, 
MA), mouse anti-total histone H3 (1: 1000, Millipore, Billerica, MA), rabbit anti-
histone yH2A.X (1:1000, Abcam, Cambridge, MA), and rabbit anti-
phosphorylated P53 (1:1000). Secondary antibodies used were horseradish 
peroxidase (HRP) anti-rabbit and HRP anti-mouse (1:10,000). 
RESULTS 
SAHA mediated cytotoxicity of adult rat opes 
Adult rat spinal cord-derived OPCs display similar susceptibility to SAHA-
mediated HOAC inhibition as previously demonstrated in postnatal mouse 
cortical OPCs (Chapter 3). Adult rat OPC primary cultures ranging from P6-P10 
are entirely A2B5+ but largely NGZ (Fig. 23A). Furthermore, they are 04+ and do 
not have any GFAP+ astrocytes, indicating the purity of this primary culture of 
adult rat OPCs (Fig. 23B). 01 and myelin basic protein (MBP) immunostaining 
are entirely absent demonstrating a continued proliferative capacity and a lack of 
spontaneous differentiation by OPCs in vitro (Fig. 23C). 3 hours after SAHA 
treatment, OPC cultures display an increase in acetylated histone H3 relative to 
vehicle treated OPCs indicating HOAC inhibition as acetylated histone subunits 
are a common HOAC substrate (Fig. 23E). Following SAHA addition, cell death is 
seen as early as 24 hours of treatment (Fig. 230). Cell survival ranges 
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approximately from 57% (2.5 IJM) to just less than 76% (250 nM) following 24 
hours of SAHA treatment. 48-72 hours of SAHA treatment results in continued 
cell death with OPC survival being as low as 14% (2.5 IJM) following 72 hours of 
treatment relative to vehicle treated OPCs (Fig. 23E). It is interesting to note that 
cell death nearly plateaus after 24 hours of exposure to 250 nM SAHA as there is 
only a 7-8% difference in cell survival between 72 hours and 24 hours of 
treatment (Fig. 23E). 
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Figure 23: HDACi-mediated cytotoxicity of rat OPCs. Spinal cord- derived rat 
OPCs are (A) A285+/NGZ, (8) 04+/GFAP" and (C) 01 "/M8P" indicating a purified 
population of OPCs that can be maintained at least through P10 without 
phenotypic drift. (0) From 24-72 hrs. following SAHA administration, significant 
decreases in cell survival are observed by MTI analyses. Cell survival is at a 
minimum at 72 hr. 1 IJM and 2.5 IJM SAHA treatment where 23.20% and 13.75% 
of OPCs remain , respectively. (E) SAHA administration results in appropriate 
drug activity in vitro as evidenced by an increase in the amount of acetylated 
histone H3 across all SAHA concentrations as early as 3 hrs. following treatment. 
* < 0.05, n = 3 for all treatments. 
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HDACi-induced DNA damage in rat OPCs 
Multiple transformed cell lines have been demonstrated to undergo DNA 
damage following small molecule HDAC inhibition (Bolden et aI., 2006; Lane and 
Chabner, 2009; Bertrand, 2010). Therefore, we investigated whether this was 
present in rat opes as well. Using an antibody against histone yH2AX, a marker 
highly suggestive of DNA double strand breaks (DSBs), multiple yH2AX+ foci are 
evident following rat OPC exposure to SAHA (Fig. 24). As early as 6 hours, 
yH2AX+ immunostaining is observed in OPC nuclei following treatment with 1 IJM 
and 2.5 IJM SAHA (Fig. 24A, D). By 12 hours following treatment, both SAHA 
drug concentrations show increased yH2AX immunostaining (Fig. 24B, E). 24 
hours following SAHA treatment, increased yH2AX staining indicates 
accumulation of DNA damage in rat OPCs over the treatment period (Fig. 24C, 
F). 24 hour treatment of oPCs with vehicle (0.003% DMSO) displayed minimal 
yH2AX+ immunostaining relative to all SAHA-treated OPCs (Fig. 24H). Western 
analysis of nuclear Iysates 18 hours following SAHA addition show a dose 
dependant accumulation of DNA damage relative to vehicle treated OPCs (Fig. 
24G). This evidence strongly suggests accumulation of DNA damage, likely to be 
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Figure 24: HDACi· induced DNA damage of rat OPCs. As early as 6 hrs. 
following SAHA administration, rat OPCs display evidence of DNA damage with 
numerous yH2AX nuclear foci at (A) 1 I-IM and (8) 2.5 I-IM SAHA. These foci 
continue to accumulate in number through (8, E) 12 hrs. and (C, F) 24 hrs. 
following SAHA treatment. The foci are considerably greater in intensity and 
number compared to (H) vehicle treated OPCs. (G) Western blot analysis shows 
an increase in yH2AX immunoreactivity from nuclear Iysates of OPCs isolated 18 
hrs. followi SAHA administration relative to vehicle treated OPCs. 
p53 and caspase activation following HDAC inhibition 
Previously, we demonstrated HDACi-mediated apoptosis in mouse OPCs 
is partly a caspase-dependant process. Caspase activation is also observed 
following SAHA treatment in rat OPCs. A dose dependant increase in cleaved 
caspase 3 is seen by 24 hours of treatment with SAHA relative to vehicle treated 
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controls (Fig. 25A). As early as 6 hours following SAHA addition, increased levels 
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Figure 25: HDACi-induced 
apoptosis is partially mediated by 
p53 activation. (A) Western blot 
analysis demonstrating caspase 
activation as indicated by the 
presence of CC3 in OPCs 24 hrs. 
following SAHA administration. (8) 
Western blot analysis of OPC total 
Iysates revealing p53 activation with 
the presence of pP53 6 hrs. following 
SAHA treatment. (C) A modest but 
significant increase in OPC survival is 
observed when OPCs are pre-treated 
with the p53 inhibitor pifithrin-a 
followed by 48 hrs. 2.5 IJM SAHA 
treatment (47.69% vs. 39.25% OPC 
survival). This suggests p53 is at least 
partly involved in mediating SAHA-
induced OPC apoptosis. n = 1, 
statistical analysis completed on 4 
replicates. S, SAHA; P, Pifithrin-a; VS, 
SAHA Vehicle; VP, Pifithrin-a vehicle. 
* < 0.05. 
Combined, these data suggest p53 activation may be responsible for caspase 
activation followed by apoptotic induction. To test this, we combined SAHA 
treatment of rat OPCs with the well known p53 inhibitor pifithrin-a. However, 
following 48 hours of 2.5 IJM SAHA (2.5 IJM}/pifithrin-a (10 IJM) treatment, only a 
modest, yet significant 8% increase in cell survival is observed (Fig. 25C). This 
increase in cell survival is also observed at a lower 1 IJM SAHA treatment (data 
not shown). These results suggest that although caspase mediated apoptosis in 
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SAHA treated OPCs is likely secondary to p53 activation, inhibiting p53 activity is 
insufficient to dramatically improve cell survival. 
HDACi does not enhance etoposide mediated OPC death 
FDA approved and clinical trial use of HDACi against malignancies 
typically involves combinatorial therapy with DNA damaging agents (Bolden et 
aI., 2006; Frew et aI., 2009). Etoposide, a topoisomerase II inhibitor, is one such 
agent and results in DNA DSBs in proliferative transformed cells. Though no 
direct effects on topoisomerase II by SAHA have been previously noted, SAHA 
has been demonstrated to work syngertistically with topoisomerase II inhibitors 
by promoting chromatin decondensation and permitting increased DNA binding 
of the topoisomerase II inhibitor potentiating DNA damage in breast cancer cell 
lines (Marchion et aI., 2004). However, it was recently demonstrated that 
etoposide, when combined with HDACi, is cytotoxic to normal postnatal rat 
cortical neurons (Michal Hetman, unpublished results). 
Therefore, we determined whether this was the case in rat OPCs as well. 
24 hour treatment of rat OPCs with etoposide, using drug ceontrations from 0.25 
IJM to 2.5 IJM, results in OPC death ranging from 32-55%, respectively (Fig. 
26A). By 48 hours of exposure to etoposide, nearly all rat OPCs are dead across 
all tested concentrations (data not shown). When 0.5 IJM or 1 IJM etoposide 
treatment is combined with 0.5 IJM or 1 IJM SAHA, a synergistic effect on rat 
OPC death is not observed (Fig. 26B-C). As etoposide induces p53-mediated, 
caspase-dependant apoptosis, the absence of synergism between etoposide and 
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SAHA suggest these compounds may result in cell death via separate DNA 
damaging pathways in rat OPCs. 
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Figure 26: SAHA does not 
enhance etoposide mediated 
death of rat OPCs. (A) Etoposide 
significantly reduces OPC survival 
24 hrs. following treatment. (B-C) 
24hr. treatment with SAHA and 
etoposide does not increase OPC 
death. S, SAHA; E, etoposide. n = 
3, * P < 0.05 
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Previously, mouse OPCs differentiated to either astrocytes or OLs in vitro 
resulted in a statistically significant but small reduction in cell survival following 
72 hrs. SAHA treatment (Chapter 3). In rat OPC-derived OLs, withdrawal of 
growth factors and transfer to differentiation media for 7 days, results in 
differentiated OPCs with phenotypic characteristics of mature OLs (Fig. 27). 
Differentiated OLs maintain their A2B5-and 04-positive immunostaining, but 
display a more complex arborization pattern of processes than the typically bi-
and tri-polar OPCs (Fig . 27A-B). Rat OLs are 01+, a cell surface marker 
associated with more mature OLs (Fig. 27C). Additionally, 01 + OLs co-express 
MBP indicating full differentiation into mature OLs (Fig. 27D-E). All cells are 
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GFAP-, therefore it is a pure population of mature Ols (data not shown). In 
contrast to mature mouse Ols, rat Ols display the same susceptibility to SAHA-
mediated HDAC inhibition as OPCs. 24 to 72 hours of 250 nM to 2.5 IJM SAHA 
treatment resulted in significantly reduced cell survival (Fig. 27F). 
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Figure 27: HDACi-mediated 
cytotoxicity of rat Ols. (A-E) 
Following transfer of OPC 
media to differentiation media, 
OPCs begin to 
morphologically appear 
mature. Following 7 days of 
differentiation, Ols are highly 
arborized and maintain (B) 04 
and (C) 01 surface marker 
expression. (D-E) Nearly all 
01 + Ols co-express MBP 
suggesting full/near full OPC 
maturation into Ols. However, 
(A) an OPC surface marker 
A2B5, maintains surface 
expression despite 
differentiation into mature Ols. 
(F) Rat Ols are just as 
susceptible to HDACi-
mediated cell death as their 
OPC predecessors. From 24-
72 hrs. of SAHA treatment, 
MTT analysis revealed 
dramatic decrease in cell 
survival with the minimum 
occurring at 72 hrs. of 
treatment at 1 IJM and 2.5 IJM 
dosages (29.51% and 14.89%, 
respectively). n = 3 for all 
treatments. * < 0.05. 
To determine whether rat Ol death is dependent on caspase activation as 
in rat OPCs we treated rat Ols with 1 IJM or 2.5 IJM SAHA accompanied by the 
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potent general caspase inhibitor q-vd-oph. 10 IJM q-vd-oph resulted in a modest 
increase in cell survival in 24-48 hour 1 IJM SAHA-treated rat OLs (Fig. 28A). An 
increase in rat OL survival is also seen with 2.5 IJM SAHA treatment for 24-48 
hours (Fig. 288). Overall, there is a 10-17% increase in rat OL survival when 
either 1 IJM or 2.5 IJM SAHA treatment is combined with 10 IJM q-vd-oph relative 
to SAHA alone suggesting that cell death is at least in part due to caspase-
mediated apoptosis. To establish whether this may be secondary to activated 
p53, 1 IJM and 2.5 IJM SAHA treatment of rat OLs was combined with pifithrin-a 
for 24-48 hours. At 24 hours following combined treatment, SAHNpifithrin-a 
treated cells showed an increase of 17-27% cell survival at 2.5 IJM and 1 IJM 
relative to SAHA only controls, respectively (Fig. 28C-D). However, this 
protective effect was transient as rat OLs with the combined treatment show no 
difference in cell survival relative to SAHA only treated cells following 48 hours of 
treatment (Fig. 28C-D). These data suggest that SAHA mediated cytotoxicity of 
rat OLs is also in part a p53 activation mediated caspase-dependent apoptosis. 
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Rat OL Survival: SAHA/Q-VD-OPH Treatment 
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Figure 28: SAHA-treated rat OL survival is improved with p53 and general 
caspase inhibition. (A) 1 0 ~M Q-VO-OPH treatment of SAHA treated OLs 
resulted in a significant increase in cell survival in 48 hrs. of 1 ~M SAHA 
treatment and (8) 24-48 hrs. of 2.5 ~M SAHA treatment. (C-O) Pifithrin-a 
pretreatment of OLs prior to SAHA administration resulted in significant OL 
survival 24 hrs. following 1 ~M and 2.5 ~M SAHA treatment but the protective 
effect was lost by 48 hrs. of SAHA treatment. Data are quantitative means +/-
SO. * P < 0.05, n=1. Q=Q-VO-OPH, VQ=Vehicie for Q-VO-OPH, S=SAHA, 
VS=Vehicie for SAHA. 
DISCUSSION 
Clinical use of laboratory and commercially developed HOAC inhibitors is 
likely to expand quickly given their considerable anti-neoplastic effects. 
Furthermore, with recent evidence suggesting improvement of survival in various 
models of neuronal death, use may include non-cancerous conditions as well 
(Abel and Zukin , 2008; Thomas, 2009). Although previously HOACi has been 
shown to result in OPC cell cycle arrest, direct HOACi mediated rat OPC 
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apoptosis had yet to be demonstrated (Marin-Husstege et aI., 2002; Shen and 
Casaccia-Bonnefil, 2008; Shen et aI., 2008). Here we show the FDA approved 
specific pan-HDAC inhibitor, SAHA, causes DNA damage, results in p53 
activation, and induces caspase-dependent apoptosis. Lastly, we demonstrate 
that pan-HDACi susceptibility is also present in rat OLs, which is in slight contrast 
to the modest cytotoxicity present in HDAC inhibitor treated mouse OLs and 
astrocytes in vitro. 
Using SAHA concentrations used to test transformed cell susceptibility 
and even show putative neuroprotective effects, considerable cell death was 
evident in adult rat OPCs as early as 24 hours following treatment. This was 
earlier than observed at the identical drugs doses in mouse OPCs (Chapter 3). 
Furthermore, following 72 hours of treatment, rat OPCs had approximately 20% 
less cell survival than mouse OPCs (Chapter 3). Taken together, these data 
suggest that adult rat spinal cord OPCs are more susceptible to SAHA mediated 
cell death than mouse OPCs. As proliferative cells are susceptible to HDACi 
mediated cell death, the increased rat OPC cell death seen following SAHA 
administration may be due to the increased in vitro proliferative potential of rat 
OPCs relative mouse OPCs (data not shown). 
HDACi has been previously described to cause DNA double strand breaks 
in both transformed cells and non-transformed human fibroblasts and is a 
common finding in HDACi treated cells (Lee et aI., 2010). Combinatorial 
treatment of an HDACi with a DNA damaging chemotherapeutic agent is typically 
seen in order to enhance transformed cell death (Bolden et aI., 2006; Marks, 
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2010). We do not see a synergistic increase in rat OPC death when SAHA 
treatment is combined with etoposide. However, with SAHA alone, as early as 6 
to 24 hours following treatment rat OPCs have numerous yH2AX+ foci, indicating 
extensive DNA damage likely in the form of DNA double strand breaks. 
Furthermore, due to the lack of synergism between etoposide and SAHA 
mediated OPC cell death, the mechanism of DNA DSB induction mediated by 
SAHA is likely different than that of etoposide. 
One possibility is increased oxidative stress secondary to HDACi resulting 
in accumulated DNA damage over time. This has been previously described 
where HDACi mediated by multiple HDAC inhibitors, including SAHA, led to 
increased reactive oxygen species (ROS) generation (Bolden et aI., 2006; Frew 
et aI., 2009). As HDACi may change global gene expression patterns, such as 
the previously demonstrated reduction in the ROS scavenger thioredoxin, this 
could lead to ROS accumulation and subsequent DNA damage (Butler et aI., 
2002; Frew et aI., 2009; Marks, 2010). Although oxidized bases typically 
undergo DNA repair that generates DNA single strand breaks (SSB) rather than 
DSBs, it is still possible that many SSBs may saturate DNA repair mechanisms 
with remaining SSBs converted to DSBs during DNA duplex unwinding if OPCs 
are undergoing replication or transcription (Jackson and Bartek, 2009; Hill and 
Lee, 2010). 
A more likely scenario involves HDACi mediated changes on the standard 
DNA DSB repair machinery in response to endogenous formation of DNA DSBs 
during DNA replication. Upon DNA DSB induction, Mre11, RAD50, and NBS1 
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(MRN Complex) recognize the site(s) of damage and catalyze the activation of 
ataxia-telangiectasia mutated (ATM) following by yH2AX foci formation (Abraham 
and Tibbetts, 2005; Lombard et aI., 2005). ATM induces either cell cycle arrest 
and/or apoptosis via phosphorylation of CHK1/CHK2 or p53, respectively 
(Lombard et aI., 2005; Cimprich and Cortez, 2008). Repair mechanisms are then 
directed into one of two repair pathways: homologous recombination or non-
homologous end-joining (NHEJ) (Lieber, 2008; San Filippo et aI., 2008; Jackson 
and Bartek, 2009). Recent evidence shows reduced expression of members of 
the MRN complex following HDACi in transformed cells putatively leading to 
reduced DNA DSB repair capacity and subsequent apoptosis (Lee et aI., 2010). 
However, the same study indicated this was not the case in normal cells (Lee et 
aI., 2010). Though we did not examine changes in MRN complex expression 
patterns in our rat OPCs, it remains possible that following HDACi there is a 
reduced capacity to repair spontaneously formed DNA DSBs. These would 
accumulate over time and with inefficient DNA DSB repair, apoptosis would then 
follow. We certainly see induction of apoptosis following HDACi as evidenced by 
p53 stabilization followed by caspase activation. Subsequent p53 activation may 
be secondary to ATM activation as the presence of yH2AX is suggestive of active 
ATM (Goodarzi et aI., 2008; Jackson and Bartek, 2009). 
Additionally, HDACi prevents post-translational deacetylation of multiple 
target proteins (Haberland et aI., 2009; Marks, 2010). Here we demonstrate drug 
activity by increased acetylation of histone H3. Successful DSB repair relies on 
open, accessible chromatin (euchromatin) in order for repair enzymes to load 
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adjacent to DSBs (Misteli and Soutoglou, 2009). This should not present as a 
problem in an environment of hyperacetylated histones as this is indicative of 
chromatin in a "relaxed" state. However, HDAC substrates are many and may 
include specific DNA DSB repair machinery (Misteli and Soutoglou, 2009; Miller 
et aI., 2010). In human cell lines, HDAC4 has been shown to be a critical 
component of the DNA DSB repair in response to yirradiation or etoposide 
(Karagiannis et aI., 2007). Additionally, SMRT-HDAC3 complex was shown to be 
necessary for proper DSB repair in mammalian cell lines (Bhaskara et aI., 2010). 
Furthermore, in saccharomyces cerevisiae, though valproic acid-mediated 
HDACi was not toxic to cells on its own, when combined with an ultraviolet-
mimetic drug, HDAC inhibition prevented deacetylation of Sae2 (human ortholog 
to CtIP). This leads to accumulation of an acetylated form of Sae2 preventing its 
interaction and subsequent displacement of Mre11 from the DSB region for 
proper DSB repair and promoting cell autophagy (Robert et aI., 2011). Therefore, 
it remains possible HDACi in OPCs results in inefficient DNA DSB repair in 
response to spontaneous DSBs, ultimately leading to cell death. 
Unexpectedly, cell death was seen in differentiated rat OLs as well. To our 
knowledge, this is the first description of extensive HDACi-alone mediated cell 
death of fully differentiated cells. The in vitro differentiation paradigm we 
employed results in cell cycle exit and full differentiation of primary rat OPCs 
(Cao et aI., 2010). Furthermore, they were positive for multiple mature OL 
markers and had not expanded in culture during the 7 days in differentiation 
media. Therefore, there is no reason to indicate they continued to retain any form 
98 
of proliferative capacity. We further show Ol death to be due in part to p53 
mediated induction of caspase-dependent apoptosis as is the case in OPCs as 
well. Though we do not have direct evidence, the similarity of cell death suggests 
this p53 mediated induction of apoptosis may be due to DNA damage. As DNA 
replication is not occurring in rat Ols, inefficient repair of endogenous DNA DSB 
accumulation during transcription may promote Ol apoptosis. However, the 
specific mechanism(s) remain to be fully elucidated. 
Overall, these results necessitate strict caution in the clinical use of HDAC 
inhibitors. Though many positive results suggest great therapeutic beneficence 
from HDACi therapy, these appear to be a model and subsequent end-point 
driven conclusions. OPCs are absolutely necessary for the normal development 
of the myelinated mammalian CNS (Knobler et aI., 1974; Wolswijk and Noble, 
1989; Noble et aI., 1992; Miller and Mi, 2007). Furthermore, Ol and myelination 
turnover in adult mammals are only beginning to become better understood 
(Fields, 2008; Ullen, 2009). As this cytotoxicity also extends to adult OPCs, we 
have yet to determine if depletion of this cellular population could be detrimental 
to the diseased, injured, or aging CNS. Furthermore, these data present an 
immediate concern for patients who are currently undergoing this form of 
treatment. SAHA is blood-brain-barrier (BBB) penetrable and may contribute to 
an as of yet unknown cognitive or motor impairment. Therefore, further study is 
necessary to define HDACi-mediated normal cell death and increase awareness 





HDAC INHIBITOR TOXICITY AND CICI 
Clinical profile of HDAC inhibitor induced toxicity 
Current clinical use of HDAC inhibitors as chemotherapeutic agents have 
revealed a toxicity profile that are somewhat common among other 
chemotherapeutic drugs, particularly as it relates to detrimental effects on 
normal, non-transformed proliferative cells. These toxicities examined thus far 
are short and mainly reversible as widespread use of HDAC inhibitors are still 
somewhat limited to advanced malignancies that often are accompanied by a 
reduced time of patient survival (Bruserud et aI., 2007). However, with current 
studies suggesting small molecule HDAC inhibitor therapy may extend to 
cancers that may have a longer period of patient survival and to non-cancer 
treatment such as use in neurological disorders, it becomes critical to investigate 
as of yet undefined toxicities that may exist with HDAC inhibitor treatment. 
The two most common toxicities observed with HDAC inhibitor therapy are 
thrompocytopenia and neutropenia. This appears to be regardless of the 
chemical structure of the HDAC inhibitor as this is seen with SAHA, depsipeptide, 
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and MS-275 (Marshall et aI., 2002; Sandor et aI., 2002; Kelly et aI., 2003; Kelly et 
aI., 2005; Ryan et aI., 2005; Bruserud et aI., 2007). Nonetheless, both 
thrombocytopenia and neutropenia secondary to HDAC inhibitor therapy are 
reversible and short-lived as recovery to normal values occurs quickly following 
cessation of therapy or may be accompanied following putative dose reduction 
(Bruserud et aI., 2007). Additionally, HDAC inhibitor effects on normal 
immunocompetent cells account for small molecule HDACi induced 
immunomodulatory effects (Bruserud et aI., 2007). An extensive review 
discusses the importance of regulation of histone acetylation status in T cell 
differentiation and rearrangement of the T cell receptor chains. HDAC inhibitor 
induced deviations in this regulation that can lead to immunosuppresion may not 
only influence risk of infection concurrent with chemotherapy but also increase 
risk of cancer relapse or progression following chemotherapy if lymphoid 
reconstitution is delayed (Bruserud et aI., 2007). 
Gastrointestinal side effects (as are typical with many chemotherapeutic 
agents) are also observed with HDAC inhibitor therapy. These include nausea, 
diarrhea, and dyspepsia depending on the HDAC inhibitor (i.e. diarrhea reported 
with depsipeptide and MS-275) and therapeutic dose used (Marshall et aI., 2002; 
Sandor et aI., 2002; Kelly et aI., 2003; Kelly et aI., 2005; Ryan et aI., 2005; 
Bruserud et aI., 2007). Among the reported adverse effects following HDAC 
inhibitor treatment, cardiac effects have also been observed. Some patients 
display electrocardiogram (ECG) abnormalities as well as dyspnea, though the 
latter was seen without the presence of other cardiopulmonary symptoms (Kelly 
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et aI., 2003; Kelly et aI., 2005; Bruserud et aI., 2007). Though not understood and 
severely limited in study, neurological toxicity has also been observed following 
HDAC inhibitor treatment. This includes decreased concentration, coordination, 
and confusion with treated patients not returning to baseline performance until 
several weeks following therapy cessation (Gilbert et aI., 2001; Bruserud et aI., 
2007). 
Chemotherapy induced cognitive impairment (CICI) 
The potential for neurological toxicity following small molecule-mediated 
HDACi is of considerable importance. As discussed in Chapter 1, CICI is only 
recently beginning to be appreciated clinically although mechanisms involved in 
its pathogenesis still remain unclear. Of the putative mechanisms that may be 
involved in CICI pathogenesis, direct or indirect DNA damage may be the most 
relevant due to the importance of maintaining genomic integrity and the number 
of chemotherapeutic agents that induce DNA damage (Ahles and Saykin, 2007). 
Normal, non-transformed cells have numerous mechanisms to repair DNA 
depending on the form of DNA damage that is present. Oxidative stress is a 
regular source for DNA damage to all cells, particularly those of the CNS (Abner 
and McKinnon, 2004; Caldecott, 2004; Ahles and Saykin, 2007; Fishel et aI., 
2007). Chemotherapeutic drugs, such as alkylating agents, induce DNA damage 
in a number of transformed cell types, however, a number of studies have found 
this damage extends to the DNA of healthy cells. Peripheral blood lymphocytes 
show evidence of DNA damage and reduced DNA repair efficacy in patients 
relative to controls, however, this was found to be the true before and after 
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chemotherapy treatment (Blasiak et aI., 2004; Nadin et aI., 2006; Ahles and 
Saykin, 2007). As chemotherapy is associated with an attenuated antioxidant 
capacity and increased production of free oxygen radicals, DNA damage 
secondary to oxidative stress in normal healthy cells should be anticipated and is 
likely a strong candidate for CICI development secondary to DNA damage in 
post-mitotic neurons (Kaya et aI., 2005; Papageorgiou et aI., 2005; Ahles and 
Saykin, 2007; Fishel et aI., 2007). 
HDAC inhibitor mediated cytotoxicity in normal cells 
In addition to the previously discussed downstream biological effects 
following HDACi, two are of great relevance in the context of DNA damage and 
genomic integrity (Chapter 1). Treatment with various HDAC inhibitors results in 
increased reactive oxygen species (ROS) generation with the addition of free-
radical scavengers attenuating tumor cell death (Bolden et aI., 2006). Increased 
cellular ROS precedes mitochondrial disruption suggesting that increased ROS 
generation is not merely an event secondary to mitochondrial damage (Bolden et 
aI., 2006; Frew et aI., 2009; Marks, 2010). Though still not entirely defined, 
increase intracellular ROS appears to be secondary to increased expression of 
thioredoxin binding protein- 2 (TBP-2), a negative regulator of thioredoxin activity 
and expression. Increased TBP-2 leads to increased inhibition of the ROS 
antioxidant scavenger reduced Thioredoxin resulting in increased ROS (Butler et 
aI., 2002; Ungerstedt et aI., 2005; Frew et aI., 2009; Marks, 2010). Ultimately, 
increased intracellular ROS will lead to DNA damage, and protein and lipid 
oxidation ultimately leading to apoptosis. 
103 
HDAC inhibitors are often co-administered with other chemotherapeutic 
agents in order to enhance transformed cell death. For instance, when 
administered in conjunction with chemotherapeutic DNA damaging agents, such 
as cisplatin or etoposide in various human cancer cell lines, they act 
synergistically to enhance tumor cell death compared to any of the agents used 
alone (Kim et aI., 2003; Frew et aI., 2009; Shiozawa et aI., 2009). Nonetheless, 
small molecule-mediated HDACi on its own has been demonstrated to cause 
DNA damage as well. HDACi's do not appear to do this directly, but it has been 
suggested HDACi mediated chromatin structural changes result in greater DNA 
exposure to damaging agents such as HDACi induced ROS (Marks, 2010). 
However, HDACi mediated disruption of DNA repair pathways leading to 
accumulation of putatively ROS induced DNA damage and subsequent 
apoptosis, is more likely to contribute to HDACi mediated DNA damage rather 
than the increased the euchromatin modification that ensues HDACi treatment. 
HDACi treatment results in the accumulation of yH2AX, a marker for DNA 
DSBs (Chapter 1). Furthermore, regulation of post-translation deacetylation of 
DNA repair proteins by HDACs play pivotal role in the successful execution of 
DNA repair (Chapter 1). Additionally, HDACi mediated transcriptional changes 
may playa role in DSB accrual (Chapter 1). HDACi reduces expression of genes 
encoding DNA repair proteins involved in HR and NHEJ mediated DNA DSB 
repair, such as RAD51 , BRCA 1, BRCA2, Ku70, Ku86, and DNA-PKcs, RAD50, 
and MRE11 (Frew et aI., 2009; Lee et aI., 2010; Marks, 2010). DNA DSB 
accumulation overwhelms repair pathways resulting in cell cycle arrest and/or 
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apoptosis, implicating perturbation of DNA DSB repair pathways as a critical 
component of HDACi mediated cell death. 
Though extensive work has gone into identifying therapeutic uses of 
HDAC inhibitors in cancer treatment, particularly as it relates to mechanisms of 
cytotoxicity towards a wide range of transformed human cell lines, studies 
investigating their toxicity towards normal cells with the potential of explaining 
clinically observed adverse effects are relatively limited (Fig. 29). Nonetheless, 
they are highly relevant, effect a variety of normal proliferative cells, and require 
further investigation to reexamine the therapeutic benefits and limits of HDACi 
therapy. Among the first studies of this nature, small molecule mediated HDAC 
inhibition by SAHA and TSA demonstrated normal renal tubular cell toxicity. At in 
vitro SAHA concentrations that have previously been extrapolated to have 
toxicity towards cancer cell lines induced apoptosis in rat renal proximal tubular 
cells in both caspase-dependent and independent mechanisms. Furthermore, 
this appears to be via a p53-independent mechanism and related to a reduction 
in anti-apoptotic protein levels (Dong et aL, 2008). This provides a putative 
mechanism for renal cell toxicity and the clinically observed, though uncommon, 
renal insufficiency following HDAC inhibitor treatment (Bruserud et aL, 2007; 
Dong et aL, 2008). 
This was followed by a number studies demonstrating HDAC inhibitor 
cytotoxicity of human mesenchymal lineage stem cells (MSCs). The pan-HDAC 
inhibitor, SAHA, and the HDAC1/class I HDAC inhibitor, MS-275 resulted in cell 
cycle arrest and subsequent apoptotic induction following treatment of human 
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MSCs isolated from healthy bone marrow donors (Oi Bernardo et aI., 2009). 
Furthermore, adipose and cord blood derived human MSCs treated with HOAC 
inhibitors valproic acid (VPA) and sodium butyrate resulted in cell cycle arrest 
and reduced their efficiency to differentiate into multiple cell types such as 
adipocytes, chondrocytes, and neurons (Lee et aI., 2009). Lastly, multiple studies 
have shown decreased bone density and increased fracture risk in animal 
models treated with SAHA or VPA (Nissen-Meyer et aI., 2007; Pratap et aI., 
2010; McGee-Lawrence et aI., 2011). In fact, prolonged treatment in humans with 
VPA reduced bone density in children and adults (Sheth et aI., 1995; Boluk et aI., 
2004; McGee-Lawrence et aI., 2011). To delve closer into these findings, a 
recent study of HOAC inhibitor-induced toxicity examined the effect HOACi has 
on maintenance of bone mass. As reported previously, in vivo administration of 
SAHA into adult mice significantly reduced bone density. Corroborative in vitro 
studies strongly suggest this loss is due to SAHA-mediated reduction of 
immature osteoblast number (McGee-Lawrence et aI., 2011). Overall, these 
findings demonstrate small molecule-mediated HOACi cytotoxicity may deplete 
the reservoir of bone marrow derived MSCs and furthermore, lead to detrimental 
changes in skeletal development and maintenance (Oi Bernardo et aI., 2009; Lee 
et aI., 2009; McGee-Lawrence et aI., 2011). 
As it became clear that HOACi may have off-target effects towards 
normal, non-transformed cells, the question remained as to how this cytoxicity is 
mediated. Additional work revealed that it is considerably similar to small 
molecule-mediated HOACi on cancerous cells. In vitro studies demonstrated an 
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increase in cell death and/or senescence when HDAC inhibitor treatment was 
combined with UV irradiation or H20 2 of MSCs (Di Bernardo et aI., 2010). 
Immunocytochemical analyses of H202 exposed MSCs when combined with 
SAHA or MS-275 treatment showed a significant increase in the number of cells 
immunpositive for the DNA oxidative damage marker 8-oxo-7,8-dihydroguanine 
(80xodG) relative to H20 2 alone (Di Bernardo et aI., 2010). The aforementioned 
study regarding increased bone loss due to reduced osteoblast number showed 
SAHA treatment alone of bone marrow stromal cells (BMSCs) was sufficient to 
cause DNA damage as demonstrated by an increase in the percentage of 
yH2AX-positive nuclei (McGee-Lawrence et aI., 2011). Lastly, though using 
relatively higher concentrations, a recent study demonstrated increased cell 
death following an increased induction of DNA double-strand breaks (DSBs) as 
indicated by the number of yH2AX-foci per cell when primary human skin 
fibroblasts were pre-treated with HDAC inhibitors followed by irradiation versus 
irradiation alone (Purrucker et aI., 2010). However, seemingly conflicting with the 
Purrucker et aJ. study, another investigation demonstrated normal human 
fibroblasts are able to repair DSBs following SAHA treatment that transformed 
cell lines cannot repair, hence establishing a preferential susceptibility of 
transformed cell lines to SAHA- mediated HDACi (Lee et aI., 2010). Nonetheless, 
there is sufficient evidence to suggest small molecule mediated HDACi may 
result in cytotoxicity towards healthy cells such as MSCs and cell cycle arrest of 
BMSCs, it remains to be seen whether it is sufficient to overcome normal cellular 
DNA repair mechanisms in many non-transformed cell types (Fig. 29). 
107 





Small Molecule HDAC 
Inhibitor Treatment withl 
without other compunds 
Bone Marrow Osteoporosis 
Re-evaluatlon of HDAC 
Inhibitor Treatment Benefits 
vs . Toxcicities 
Neuronal and OPC 
Cytotoxicity 
Dysmyelination andl 
or Cognitive Deficits 
Figure 29: Current knowledge of SAHA-mediated normal cell toxicity and 
potential clinical toxicities. HDACi mediated by SAHA has been demonstrated 
to have toxicity towards multiple normal cell types that may have clinical 
implications affecting multiple organ systems. The pathway outlined in red 
requires further investigation and includes the above discussed OPC toxicity in 
the presence of SAHA. 
Cytotoxic effects of small molecule-mediated HDACi on OLs 
As discussed in chapter 1, HDAC activity plays a critical role in regulating 
OPC maturation into mature myelinating OLs, whereby HDACi prevents OPC 
maturation into OLs and may even promote their differentiation towards a 
neuronal lineage (Shen and Casaccia-Bonnefil, 2008; Copray et aI., 2009; Dietz 
and Casaccia, 2010). The experimental evidence described herein go a step 
further and demonstrate small molecule-mediated HDACi alone at concentrations 
at and below those extrapolated for use against a variety of cancers causes 
increased cortically-derived mouse postnatal OPC cell death both in vitro and in 
vivo. Furthermore, this is at least in part due to increased caspase-dependent 
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apoptosis and is secondary to an induction of widespread DNA DSBs observed 
as early as six hours following SAHA treatment in adult spinal cord-derived rat 
OPCs. However, the effect of SAHA administration in vitro on mature OLs is not 
entirely clear. Differentiated mouse OPCs did show significant increase in cell 
death following SAHA treatment but these may have been cells that had yet to 
fully mature and therefore, may have still been susceptible to SAHA-mediated 
cytotoxocity. Despite this, rat OPCs that were permitted to differentiate into fully 
mature OLs remained susceptible to SAHA-induced cytotoxicity (Chapter 4). 
Though, as far as we are aware, this is the first study that demonstrates 
HDACi treatment resulting in accumulation of DNA DSBs with subsequent cell 
death described in the oligodendroglial lineage, detrimental effects of 
chemotherapy induced dysmyelination and OL death have been previously 
described. Systemic administration of chemotherapeutic agents carmustine, 
cytosine arabinoside, and cisplatin were shown to illicit cytotoxicity towards CNS 
progenitor cells, including OPCs, in multiple regions of the mouse brain (Dietrich 
et aI., 2006). Furthermore, intraperitoneal administration of 5-flurorouracil (5-FU), 
a chemotherapeutic agent used comprehensively in the treatment of colorectal 
cancer as well as an adjuvant therapy in a wide range of other cancers, caused 
considerable OL cell death in vitro and in vivo. Additionally, as late as seven 
weeks following 5-FU administration, extensive myelinopathy accompanied by 
reduced cellularity were observed by ultrastructural and immunohistochemical 
analyses of the corpus callosi of adult mice (Han et aI., 2008). These ultimately 
corroborated clinical data demonstrating white matter abnormalities and cognitive 
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impairments in patients receiving treatment with these chemotherapeutic agents 
providing strong evidence of the involvement of OL loss in CICI pathogenesis. 
DUALISM OF HDAC INHIBITION 
As extensively reviewed and previously discussed in chapter 1, small 
molecule-mediated HDACi have also been recently identified as being beneficial 
in a number of neurological disease models. Briefly, these include 
neurodegenerative diseases such as Parkinson's and Huntington's disease, 
Rubenstein-Taybi syndrome, Rett syndrome and ischemic stroke models (Abel 
and lukin, 2008; Kazantsev and Thompson, 2008; Colussi et aI., 2010). 
Additionally, studies investigating the use of HDAC inhibitors for the treatment of 
psychiatric disorders such as schizophrenia, bipolar disorder, and depression 
have also suggested their use to improve disease outcome in animal models 
(Abel and lukin, 2008; Grayson et aI., 2010). More specifically, it was recently 
demonstrated that mouse intra-hippocampal administration of the HDAC inhibitor 
MS-275 promoted anti-depressant like activity such as reversal of defeat-induced 
deficit of sucrose preference and lessening in social avoidant behavior 
(Covington et aI., 2011). Lastly, animal models of neuromuscular diseases such 
as amyotropic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and 
Friedreich's ataxia treated with HDAC inhibitors have also demonstrated some 
degree of therapeutic beneficence (Abel and lukin, 2008; Kazantsev and 
Thompson, 2008; Colussi et aI., 2010). 
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However, a relevant question necessarily follows: How do we consolidate 
the extensive experimental evidence demonstrating the cytotoxic effects of 
HDAC inhibitors with its neuroprotective and neurotrophic effects in a multitude of 
disease models, most notably of those being HDAC inhibitor treatment of 
neurological disorders? Often times these differences are attributed to drug 
dosage and/or delivery variability. However, in the case of HDAC inhibitors 
experimental treatment paradigms showing both cytotoxic and cytoprotective 
effects have been relatively similar. Differences may also be explained by the 
inability of transformed cells to overcome the induction of DNA damage by HDAC 
inhibitors, whereas normal cells are either resistant and/or have effective DNA 
reparative processes in place thereby allowing the demonstration of HDAC 
inhibitors cytoprotective properties. However, as discussed above, normal cells 
are susceptible to small molecule-mediated HDACi cytotoxicity at concentrations 
comparable, if not less than those of cancerous cells (Bruserud et aI., 2007; 
Dong et aI., 2008; Di Bernardo et aI., 2009; Lee et aI., 2010; McGee-Lawrence et 
aI., 2011). Perhaps the variation of HDACi on proliferative versus differentiated 
cells may explain this difference in cellular effect. Actively dividing cells may be 
more susceptible to DNA damaging agents such as HDAC inhibitors and thereby 
are overcome by its cytotoxic induction whereas differentiated cells, such as 
neurons, can withstand this. However, preliminary evidence suggests that at 
least rat mature OLs are as susceptible to HDACi mediated cytotoxicity as their 
proliferative OPC counterparts (Chapter 4). Additionally, rat cortical neurons 
treated with both an HDAC inhibitor and a DNA damaging agent topoisomerase II 
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inhibitor, etoposide, result in extensive cytotoxicity (unpublished data, privileged 
communication with Dr. Michal Hetman). 
Rather than searching for differences in the status of their targets, 
emphasis needs to placed on the direct downstream effects that follow HDACi 
that are likely similar amongst many different cell types, normal or transformed. 
Similar mechanisms have been described to explain both the cytotoxic and 
cytoprotective effects of HDAC inhibitors. They involve changes in gene 
transcription and post-translational modification of protein acetylation status 
(Colussi et aI., 2010; Marks, 2010). These two mechanisms are also linked as 
post-translational modification of trans-acting factors and/or of histones lead to 
changes in chromatin structure that may directly alter gene transcription. Such 
changes include increased expression of pro-apoptotic genes and death 
receptors and ligands in transformed cells, but also increased expression of 
target disease genes normally silenced in the disease phenotype, such as the 
frataxin gene in Friedreich's ataxia (Kazantsev and Thompson, 2008; Marks, 
2010). However, changes in acetylation status of proteins also affect proteins 
that are not involved in transcription but are critical to normal cell function and 
survival. These, for example, include regulation of microtubule dynamics 
specifically by HDAC6, stabilization of p53, and modification of DNA repair 
pathways (Kazantsev and Thompson, 2008; Misteli and Soutoglou, 2009; Miller 
et aI., 2010). Yet, often studies demonstrating protective effects following HDACi 
are largely endpoint driven whereby they may not experimentally investigate 
known downstream cytotOXic effects of HDACi therapy. 
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Therefore, to further understand this incongruity in the outcome of HDAC 
inhibitor treatment it is perhaps important to appreciate a critical concept: 
Compounds that modify global cellular processes invariably have global cellular 
consequences. However, the term global does not refer to transcriptional 
changes as numerous studies indicates that HDACi results in transcriptional 
expression changes that effect subsets of genes (Kazantsev and Thompson, 
2008; Thomas, 2009; Colussi et aI., 2010). Rather, although HDAC inhibitors 
alter the balance of expression between pro-survival and pro-apoptotic genes 
seemingly in favor of one or the other depending on the question being 
investigated, they too are likely affecting other downstream processes that have 
been previously described in other studies such as DNA repair efficiency, 
reactive oxygen species (ROS) generation, and/or cell cycle arrest that may 
likewise be cytotoxic to otherwise healthy cells not central to the experimental 
question. 
Furthermore, the effects of HDACi will depend on the specific cell 
population being investigated as systemic HDAC inhibitor administration in 
experimental animal models and humans exposes the majority, if not all cell 
types- normal, diseased, or transformed- to their putative downstream effects. As 
discussed above, normal cell types such as renal tubular cells and MSCs are 
susceptible to HDAC inhibitor induced apoptosis. Also as discussed above, this 
furthermore extends to OPCs, where either cell cycle arrest may occur 
preventing differentiation into mature OLs or induction of apoptosis following 
DNA DSB formation (Chapters 1,3, & 4). 
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Additionally and likely driving some degree of the cell specific HDACi 
responses observed are that the variety of effects mediated by HDAC inhibitors 
may simply be a consequence of which HDAC isoforms are normally expressed 
in different tissues and cell types. In fact, many studies as discussed by a 
recently published review have revealed that even in the CNS, HDAC isoform 
expression patterns vary considerably amongst many brain regions (Le. 
cerebellum, striatum, amygdala) and the spinal cord (Thomas, 2009). Needless 
to say, this offers another level of complexity of HDACi treatment that could 
explain its divergent effects. A recent study demonstrated that primary ventral 
midbrain neurons are susceptible to caspase-independent apoptosis following 
HDAC inhibitor treatment. They also found that this toxicity did not extend to 
primary cortical neurons (Forgione and Tropepe, 2011). This difference in 
cytotoxicity could putatively be explained either by varying HDAC isoform 
expression patterns between the two neuronal populations, though this possibility 
has yet to be investigated. 
Lastly, differences in HDAC expression, even within the same cell type, 
also likely depend on the cell context- whether it is functioning normally, 
stressed, or dying. This likely depends on the cellular environment at that time of 
HDAC inhibitor administration. To illustrate this point, there are a number of 
studies largely originating from one group that have defined OPC cell cycle arrest 
or perhaps even loss of glial lineage restriction upon differentiation with HDACi 
(Chapter 1). We took this story a step further with experimental evidence 
demonstrating HDACi results in OPC DNA damage with subsequent cell death in 
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vitro and in vivo. However, a recent publication clearly shows white matter 
preservation in an ex vivo prep under ischemic conditions with small molecule-
mediated HDACi (Baltan et aI., 2011). We can reconcile the two contrasting 
results by considering the cellular context at the time of HDACi- where 
cytotoxicity is present following HDACi in healthy, normal functioning OPCs 
whereas cytotoxicity may be attenuated if OPCs are in the presence of a greater 
stress than HDACi, such as ischemia. 
Overall, non-transformed cell types are just as susceptible, if not more, to 
HDACi mediated cytotoxicity relative to cancer cells as evidenced by its effect at 
relatively low drug concentrations on MSCs, osteoblasts, and OPCs (Di Bernardo 
et aI., 2009; McGee-Lawrence et aI., 2011). Yet, a large number of studies and 
reviews have clearly demonstrated the neuroprotective effects of HDACi despite 
a minority of findings suggesting HDAC inhibitors may be neurotoxic. What drives 
these differing susceptibilities and responses to HDACi, particularly in healthy 
non-transformed CNS cells are likely to be multifactorial and require much 
needed investigation to both limit normal cell cytotoxicity while specifically 
enhancing HDAC inhibitors' putative protective effects. 
FUTURE HDAC INHIBITOR DEVELOPMENT AND THERAPY 
As the evidence for therapeutic use of HDAC inhibitors increases with a 
concomitant increase in the number of clinical trials using these drugs in an 
increasing variety of diseases, fully understanding toxicities affiliated with HDACi 
is of great importance. The general direction of HDAC inhibitor development is 
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towards discovery and synthesis of HDAC isoform selective compounds 
(Thomas, 2009; Bertrand, 2010). Though this is proposed to likely reduce non-
specific effects, particularly towards healthy cells, greater evidence is still needs 
to be demonstrated that isoform selective inhibition is sufficient. 
With the data presented in the above chapters as well as slowly increasing 
evidence of HDAC inhibitor cytotoxicity towards normal, non-transformed cells, I 
propose two additional measures need to be taken as well. Assess clinical use, 
safety, and promote future development of HDAC inhibitors that have little to no 
BBB penetrability. Currently, HDAC inhibitor development is trying to increase 
BBB penetrability for use against CNS tumors and neurodegenerative conditions. 
However, with the possibility that the scientific community is being a somewhat 
hasty in progressing HDAC inhibitors into the clinical trials for use in 
neurodegenerative conditions and traumas, HDAC inhibitors in use against a 
variety of malignancies that only remains in the periphery would spare any as of 
yet fully defined CNS toxicities while still maintaining their well documented 
efficacy against a peripheral malignancy. This would allow us time to understand 
the limits of HDAC inhibitor therapy in the context of CNS disease while providing 
oncologists and cancer patients with a potential new drug that may increase 
survivability. 
Secondly, there needs to be a greater appreciation amongst the basic 
neuroscience community regarding both the implications and relevance of 
investigating CNS neurotoxicity secondary to chemotherapeutic agents. 
Cognitive impairment prior to, during, and following chemotherapy is being better 
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assessed clinically than in years past (Argyriou et aI., 2010; Janelsins et aI., 
2011). Yet it appears neuroscientists investigating this phenomenon are still 
considerably limited. Due in large part to the amount of funding and societal 
need, cancer research is expansive leading to a seemingly uninterrupted flow of 
rapid developments, synthesis of new drugs, and novel treatment strategies. 
With now an improved appreciation for the significance of CICI development, I 
would like to see the neuroscience community dramatically increase its efforts 
investigating CNS toxicities of new chemotherapies as they are developed in 
basic science labs. 
As cancer therapies improve and the number of cancer survivors 
continues to increase in the ensuing years, we need to no longer rely solely on 
patient's cognitive tests and imaging studies after drug treatment as effects may 
be irreversible. Rather, putative neurotoxicity and oligodendrotoxicity profiles of 
old and new chemotherapeutic drugs will be determined prior to clinical trials 
which would limit or entirely prevent exposure to CNS toxic agents of which may 
not have sufficient benefit to warrant clinical use. This too would have the added 
benefit of increasing our knowledge on what biological processes (as they are 
altered by chemotherapeutic agents) CNS cells may either be tolerant! resistant 
or susceptible to. With the potential of being applicable to other subspecialties of 
neuroscience research, such information may greatly further our understanding 
of other neurological disorder models. 
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SUMMARY 
HDACi, CICI pathogenesis, and concluding remarks 
Despite future directions of HDAC inhibitor drug development that have 
greater HDAC isoform selectivity resulting in cellular specific affects that 
decrease potential toxicities, previously developed HDAC inhibitors, most notably 
SAHA, are currently in use as a chemotherapeutic agent and may have unknown 
adverse CNS toxicities (Fig. 30). For SAHA alone (trade name Vorinostat®, 
Zolinza®), over 180 clinical trials are listed-and the number increases 
dramatically when including clinical trials for other HDAC inhibitors such as MS-
275 (trade name Entinostat®). Furthermore, with extensive experimental 
evidence indicating cytoprotective effects of HDACi therapy in disease models 
that include neurological and psychiatric disease, cardiovascular disease, and 
autoimmune disorders, there already is an endorsement for administration of 
HDAC inhibitors for treatment in non-cancer related illnesses. Therefore, it 
becomes more pressing than ever to fully understand the CNS toxicities that are 
associated with small-molecule- mediated HDACi. 
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Healthy OPC Stressed OPC Dead OPC 
Figure 30: Model of HDACi-induced OPC cytotoxicity and implications in 
CICI pathogenesis. Small molecule-mediated HDACi by HDAC inhibitors such 
as SAHA results in extensive DNA damage (likely DNA DSBs) which partly 
promotes P53-caspase mediated apoptosis. Previous studies have demonstrated 
VPA mediated OPC cell cycle arrest and inhibition of OPC differentiation due to 
alterations in the OPC transcriptional program which favor inhibition of OPC 
differentiation (Chapter 1). However, VPA induced cell cycle arrest may also be 
secondary to HDACi-induced DNA damage. Regardless, whether it is promotion 
of OPC apoptosis or prevention of OPC maturation, myelination abnormalities 
would likely result, which would further clinically manifest itself with reduced 
cognitive function amon other CNS impairments. 
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As HDACi-mediated cytotoxicities are clearly evident in neurons as well as 
Ols, and more specifically OPCs, it's necessary to assess if HDACi in patients 
currently receiving therapeutic HDAC inhibitors result in any CICI induction (Fig. 
30). Though not given nearly as much attention as their neuronal counterparts, 
OPCs and mature Ols have a critical role in CICI pathogenesis that has yet to be 
fully defined and appreciated. Many studies and thorough reviews have 
illustrated the importance of myelination and white matter normality as it relates 
to axonal integrity, learning, memory, and overall cognitive function (Fields, 2008; 
Nave, 2010). Furthermore, the studies described herein in addition to the 
previously discussed studies assessing the affects of a number of 
chemotherapeutic agents such as cisplatin and 5-FU reveal that Ol death and 
white matter abnormalities may manifest either acutely or in a delayed fashion 
following chemotherapeutic drug administration and therefore contribute to 
progressive CICI development over a large time course (Han et aI., 2008; 
Meyers, 2008). 
As the use of HDAC inhibitors for a large variety of malignancies will likely 
increase over the coming years, it becomes necessary to clearly characterize all 
cytotoxicities that occur due to its use- particularly its effects on the CNS. 
However, concerns over CNS toxicity have remained largely marginalized by the 
numerous reports demonstrating the neuroprotective potential of HDAC inhibitors 
in an assortment of neurological disorders. Consolidating the two roles these 
class of drugs play- cytotoxicity versus cytoprotection- when drug concentration, 
administration, and duration methods are equal is a relatively complex 
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undertaking and depends on a number of factors such as cell lineage, cell 
context and environment, and whether the cell is proliferative or fully 
differentiated. Therefore, thoroughly investigating the role HDACi has on survival 
of cells within the oligodendroglial lineage will not only shed insight on new drugs 
and mechanisms involved in CICI pathogenesis but further our understanding on 
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